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INTRODUCTION 
 
1.1.   INTRODUCTION TO MEDICINAL CHEMISTRY 
 Medicinal chemistry is a science having its roots in all branches of 
chemistry and biology. It involves isolation, characterization and synthesis of 
new compounds that can be used for prophylaxis and curing of diseases. 
Medicinal chemistry thus forms the chemical basis of therapeutics. 
 The subject of medicinal chemistry explains the design and production 
of compounds that can be used for the prevention, treatment or cure of human 
and animal diseases. Medicinal chemistry includes the study of already existing 
drugs, of their biological properties and their structure-activity relationships [1]. 
Medicinal chemistry was defined by IUPAC specified commission as it 
concerns the discovery, the development, the identification and the 
interpretation of the mode of action of biologically active compounds at the 
molecular level 
 Medicinal chemistry is an interdisciplinary science. It has been stated   
that “Medicinal chemistry concern the discovery, the development, the 
identification and interpretation of the mode of action of biologically active 
Compounds at the molecular level”. Evidently it touches all branches of 
Chemistry and biology. Medicinal chemistry is also treated under the terms 
pharmaceutical chemistry, molecular pharmacology, bio-organic chemistry, 
and selective toxicity.  
 The focus is mainly on organic medicinal substances. The organic drugs 
may be of natural or synthetic origin. The synthetic drugs have resulted by 
simple or more modification of the structures of the natural drugs, or by pure 
synthesis. The other areas of collaboration in medicinal chemistry includes 
biology, computer aided drug design (CADD), 3-D QSAR, X-ray 
crystallography, metabolism, pharmacokinetics, legal and regulatory affairs, 
clinical franchise  management, pharmaceutics and process research chemistry. 
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 Chemists and pharmacologist concerned with the synthesis and 
evaluation of new compounds. The correlation of structure and activity in such 
summaries stimulates the visualization of new molecular structure and leads to 
the synthesis and testing of new compounds 
 The practice of medicinal chemistry is devoted to the discovery, 
development of new agents for treating diseases. Most of the activity in this is 
devoted to new natural or synthetic organic compounds. The process of 
establishing a new drug is exceedingly complex and involves the talents of 
people from a variety of disciplines, including chemistry, biochemistry, 
physiology, pharmacology, pharmaceutics and medicine. Medicinal chemistry 
is concerned mainly with the organic analytical and biologic interface of 
chemistry and biology. There is a considerable overlap with chemical aspects 
of this process. Thus it occupies a strategic position at the other disciplines. 
 
1.2 GENOTOXIC IMPURITIES 
 Impurities are the unwanted chemicals developed during formulation or 
that remain with the active pharmaceutical ingredients (APIs). The presence of 
these small amount of unwanted chemicals may influence the safety and 
efficacy of the pharmaceutical products (2). 
 As per ICH guideline impurities are classified in to three types- organic, 
inorganic and process based impurities. 
 Organic Impurities:    
Impurities arises during manufacturing process and/or during storage of the 
drug substance. These impurities include 
 Starting or intermediate impurities,  
 By-products impurities,  
 Degraded products impurities, 
 Enantiomeric impurities. 
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Inorganic impurities: 
  These type of impurities raised by manufacturing processes which are 
used in bulk drugs formulation. This impurities are normally known and 
identified. It includes  
 Heavy metal impurities, 
 Material impurities (filter aids, charcoal) 
 Residual solvent impurities.  
 
Process Based Impurities:  
 Impurity produced due to environmental defect, factor defect, mutual 
interaction among ingredients, functional group reaction degradation. (3, 4) 
 Various regulatory authorities like ICH, United States FDA, Canadian 
Drug and Health Agency are valued to the purity and safety requirements and 
the identification of impurities in Active Pharmaceutical Ingredient’s. 
Qualification of the impurities is the process of obtaining and evaluating data 
that establishes biological safety and purity of an individual impurity. 
Chromatographic and Spectroscopic techniques is used to identify the 
impurities, either alone or in combination with other techniques. TLC, HPLC, 
HPTLC, AAS also used for detecting and characterizing impurities in active 
pharmaceutical ingredients. 
 Impurity profiling is the process of acquiring and evaluating data that 
establishes biological safety of an individual impurity. Impurity is considered 
as any other organic material, besides the drug substance, or ingredients, arise 
out of synthesis or unwanted chemicals that remains with API’s. The control of 
impurities is currently a critical issue to the pharmaceutical industry. 
 Safety and efficacy of pharmaceuticals are fundamental issues of 
importance in drug therapy. The safety of a drug is determined by its 
pharmacological and toxicological profile of a drug as well as the adverse 
effects caused by the impurities in bulk dosage forms. 
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 Identification of impurities is done by TLC, HPLC. The advent of 
hyphenated techniques has revolutionized impurity profiling, by not only 
separation but structural elucidation of impurities as well. The most 
exploited techniques, for impurity profiling of drugs are LC-MS-MS, LC-
NMR, LC-NMR- MS, GC-MS, and LC-MS. 
 Geotaxis impurities are chemical compounds that can produce genetic 
mutations and chromosomal rearrangements and can act as carcinogenic 
compounds in target cell. The compounds can cause damage to DNA cells by 
alkylation or other interactions that can lead to mutation of the genetic codes. 
Impurities are generated during manufacturing of active pharmaceutical 
ingredients from the source of starting material, reagents, solvents, 
intermediates, catalysts and reaction by-products. Particularly, potential 
genotoxic impurities (PGI) shows structural alert functionality and causes 
genetic mutations, chromosomal breakage, chromosomal rearrangements and  
may cause cancer in human being (5). 
 The International Conference on Harmonisation  published guidelines in 
the late 1990s on pharmaceutical products and impurities of drug substances. In 
the guidelines, genotoxicity tests designed for detecting compounds that induce 
genetic damage directly or indirectly by invitro and invivo. 
 However, several important issues have not been addressed in the 
guidelines, for example, the acceptable levels of impurities in drugs during 
development as well as the control of genotoxic impurities.  The series of 
thresholds described in ICH Q3A(R) that trigger reporting, identification, and 
qualification requirements. As per Threshold of Toxicological Concern value is 
equal or more than that of 1.5 µg/day intake of a genotoxic impurity is 
considered  as a acceptable risk  for most pharmaceuticals. 
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Thresholds 
Maximum daily dose 
≤2 g/day >2 g/day 
Reporting  threshold 0.05% 0.03% 
Identification threshold 0.10% or 1.0 mg per day intake  (whichever is lower) 0.05% 
Qualification threshold 0.15% or 1.0 mg per day intake  (whichever is lower) 0.05% 
 
Table No 1: Threshold of toxicological concern value. 
ICH Guidelines for Genotoxic Impurities:  
 Impurities in New Drug Substances - Q3A(R2)  (Current Step 4 version, 
dated 25 October 2006)  
 Impurities in New Drug Products - Q3B(R2),  (Current Step 4 version, 
dated 2 June 2006) 
 Impurities: Guideline for Residual Solvents - Q3C (R3),  (Current Step 4 
version, parent guideline, 17/7/97, revised November 2005) 
 
  The qualification threshold is 0.15% or 0.05%, respectively, if the 
maximum daily dose of the drug is lower or higher than 2 grams. The Q3A 
guideline also introduces the concept of TDI (Total Daily Intake) of the 
impurity, which is expressed in mg/person/day, rather than in concentration. 
The structure of impurities exceeding the identification threshold (0.10% or 
0.05% depending on the daily dose of the drug) must be elucidated. With the 
identification of the structure it is possible to assess the analytical response 
factor of the impurity. According to Q3A the qualification threshold in terms of 
TDI corresponds to 1 mg/person/day of the impurity. 
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Genotoxic impurity study thresholds levels are given below: 
Max daily 
dose 
Qualification 
Threshold 
Identification 
Threshold 
Reporting 
Threshold 
≤2g/day 0.15%/1.0mg/day (lowest) 
0.10%/1.0mg/day 
(lowest) 0.05% 
>2g/day 0.05% 0.05% 0.03% 
Table No 2: Thresholds levels as per ICH daily dose. 
 
1.3 DALFAMPRIDINE  
 Dalfampridine otherwise called as 4-Aminopyridine , 4-AP, fampridine. 
Dalfampridine is the first drug approved in the United States by USFDA to 
improve walking in patients with multiple sclerosis . Fampridine is also 
marketed as Ampyra in the United States by Acorda Therapeutics and as 
Fampyra in Europe. In Canada, the medication as been approved for use by 
Health Canada since February 10, 2012. 
 4-Aminopyridine is non-selectively block K+ channel, which is actively 
blocking a wide variety of potassium channels with different state 
dependences. Therefore, in search for clues for the structural determinants of 
K+ channels that are important for the state dependences of drug-channel 
interactions, 4-AP serves as a useful tool. Potassium channel blocker used to 
help multiple sclerosis patients walk . This is the first drug that was specifically 
approved to help with mobility in these patients. 
  Dalfampridine has to improve visual function and motor skills and 
relieve fatigue in patients with multiple sclerosis (MS). 4-AP is most effective 
in patients with the chronic progressive form of MS, in patients who are 
temperature sensitive, and in patients who have MS for longer than three years. 
Side effects of dalfampridine is shown to be less than 5 % in all studies like 
dizziness, nervousness and nausea and the incidence of adverse effects. 
Potassium channel blockade reverses this effect. 
Introduction  
Page 7 
  It is very effective avicide and bird repellent and is highly toxic to 
human; it strongly excites central nervous system. It was undergoing Phase III 
clinical trials as of 2008 (6).  
 Currently, the McDonald criteria constitute the most widely used 
diagnostic modality because they focus on clinical, laboratory, and radiologic 
data of MS lesions and their dissemination in time and space (7). More than 90 
% of patients with MS report difficulty in walking (8). An oral medication, 
dalfampridine is quickly and completely absorbed in the gastrointestinal (GI) 
tract. A slight and clinically insignificant increase in the Cmax of 
dalfampridine is noted when it is taken with food; therefore, this drug may be 
taken without regard to meals. 
 Cells of the immune system, such as B and T lymphocytes and 
macrophages, express voltage activated K+ channels also sensitive to 4-AP .  In 
addition, 4-AP blocks different lymphocytic functions, including mitogen 
induced cell proliferation (9) and killing by natural killer (NK) cells and 
cytotoxic T cells. However, the concentration of 4-AP required to inhibit cell 
functions may be 5-10 fold higher than that required to block K+ channels 
during voltage clamp experiments Part of this effect may result from a decrease 
in the channel blocking potency of 4-AP in the presence of serum contained in 
the culture medium.  
 The FDA’s approval of dalfampridine was based on the results of one 
phase 2 and two phase 3 randomized, double-blind, placebo-controlled, 
parallel-group clinical trials (MS-F202 and MS-F203) (10). During the study 
period, 300 patients were randomly assigned to receive either dalfampridine 10 
mg or placebo twice daily. After the 14-week treatment period, patients were 
observed for an additional four weeks.  Multiple sclerosis (MS) is a 
neurological disorder that affects approximately 400,000 people in the U.S. and 
2.5 million people worldwide, with women twice as likely to be affected as 
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men (11,12). MS is manifested by mental and physical symptoms characteristic 
of the illness.  
 The FDA granted dalfampridine orphan drug status, which will provide 
market exclusivity for the drug for 7 years (13). Dalfampridine is a potassium 
channel-blocker that enhances conduction in focally demyelinated axons, 
improves synaptic transmission and potentiates muscle contraction (14). The 
clinical use of dalfampridine is found to improve walking in patients with 
multiple sclerosis (MS) as demonstrated by an increase in walking speed. It has 
shown efficacy in patients with all four major types of MS (15). Dalfampridine 
is mostly unbound to plasma protein (97–99 %) and the apparent volume of 
distribution is 2.6 L/kg. Studies with human liver microsomes indicated that 
CYP2E1 was primarily accountable for the 3hydroxylatoin of dalfampridine. 
The common adverse effects in patients administered dalfampridine include 
urinary tract infections, insomnia, dizziness, headache, nausea, weakness, back 
pain, ataxia and visual disturbances(16). 
 During the synthesis of Dalfampridine some impurities formed such as 
1,2-Di(pyridine-4-yl)hydrazine, 4-Aminopyridine-N-oxide, 2-Aminopyridine, 
3-Aminopyridine, Pyridine-4-carboxamide, Pyridine-4-carboxylic acid, (1, 3-
Di (8yridine-4-yl) urea, 4-Amino-3-Chloro-Pyridine, 4-Cyanopyridine, 4-
Amino-3,5-Dichloro Pyridine, N-(4-Pyridyl)-2-Hydroxybutyramide) are 
identified PGIs which is tabulated as follows: 
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S.NO CHEMICAL NAME STRUCTURE 
1. 1,2-Di(pyridine-4-yl) hydrazine 
N
NHN
NH
 
2. 4-Aminopyridine-N-oxide 
N
NH2
O  
3. 2-Aminopyridine N
NH2
 
4. 3-Aminopyridine 
N
NH2
 
5. Pyridine-4-carboxamide 
N
O NH2
 
6. Pyridine-4-carboxylic acid 
N
O OH
 
7. (1, 3-Di (pyridin-4-yl) urea N
H
O
N
H
NN
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S.NO CHEMICAL NAME STRUCTURE 
8 Fampridine-d4 
N D
D
NH2
D
D
 
9 4-Amino-3-Chloro-Pyridine 
N
NH2
CL
 
10 4-Cyanopyridine  N
CN
 
11 4-Amino-3,5-Dichloro Pyridine 
N
LC
NH2
CL
 
12 N-(4-Pyridyl)-2-Hydroxybutyramide) 
N
NH
O
HO
CH3
 
 
Table No 3: Dalfampridine genotoxic impurities. 
 
MODE OF ACTION OF ANTIBACTERIAL  AGENTS: 
 Antibacterial drugs interfere chemically with the synthesis of function of 
vital components of bacteria. The cellular structure and functions of eukaryotic 
cells of the human body. These differences provide us with selective toxicity of 
chemotherapeutic agents against bacteria. 
 Antimicrobial drugs may either kill microorganisms outright or simply 
prevent their growth. There are various ways in which these agents exhibit their 
antimicrobial activity. 
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 They may inhibit : 
(1)  Cell-wall synthesis 
(2)  Protein synthesis 
(3)  Nucleic acid synthesis  
(4)  Enzymatic activity  
(5)  Folate metabolism 
(6)  Damage cytoplasmic membrane 
 
 
Fig No 01: Common Mechanisam of  Bacterial Growth Inhibition 
 
SCREENING OF ANTI BACTERIAL ACTIVITY 
 The condition which must be fulfilled before screening the antibacterial 
activity.The organism and drug substance to be evaluated should be contacted 
intimately. The microorganism’s growth should be maintained under 
conditions like incubation period, temperature, nutrient media, etc. Throughout 
the study conditions were maintained.  
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Preparation of different media: 
 The growth media required for evaluation of antibacterial activity was 
prepared as per the procedure reported in Himedia manual, as follows: 
 
1. Muller Hinton Agar: 
It mainly contains following content, 
Ingredients       Quantity (Gm/L) 
Beef heart infusion,       2.00 
Casein acid hydrolysate     17.50 
Starch, soluble      1.50 
Agar        17.00 
 
Procedure: 
 Suspend 38 grams in 1000ml distilled water. Mix well and boil the 
media to dissolve completely. autoclaving at 15 lbs pressure (1210C) for 15min 
sterilisation has done. Pour the media after mixing thoroughly. 
 
2. Tryptic soya bean broth:  
 It mainly contains following content 
 
Ingredients       Quantity (Gm/L) 
Casein (enzymic hydrolysate)     18.00 
Papaic digest of soybean     2.00 
Sodium chloride        6.00 
Dipotassium phosphate     3.50 
Dextrose       3.50 
 
Procedure: 
 Suspend 30grams of Tryptic soya bean broth powder in one litre of 
distilled water. Medium was boiled to dissolve completely. Autoclaving at 
15lbs pressure (1210C) for 15 minutes. 
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Methods used for primary and secondary screening: 
Primary Screening Method: The test and control drugs were diluted 
using sterile methanol in 1000 microgram per ml (µg/ml), 500.0 microgram per 
ml , 250.0 microgram per ml from which 100 µl of solution taken in the cups to 
obtain a concentration of 100 microgram per ml, 75 microgram per ml and 50 
microgram per ml respectively. A methanol control was also run along with 
test and the reference drug. The promised result from the synthesized 
molecules was tested by primary screening for all microorganisms by second 
set dilution. 
Secondary Screening Method: The promised results from the 
synthesized molecules in primary screening were diluted using sterile methanol 
as 100 microgram per ml, 75 microgram per ml, 50 microgram per ml from 
which 100 µl of solution taken in the cups to obtain concentration of 0.8 
microgram per ml, 0.4 microgram per ml, 0.2 microgram per ml respectively. 
 
CHEMISTRY 
 4-Aminopyridine (4-AP, fampridine, dalfampridine) is an organic 
compound with the chemical formula C5H4N-NH2 and molecular weight 94.04 
gm/mole. It is chemically pyridine-4-amine, used primarily as a research tool 
for subtypes of potassium channels. It is use to manage some of the symptoms 
of multiple sclerosis and is indicated for symptomatic improvement of walking 
in adults with several variations of the disease. 
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Molecular Structure  :  
N
NH2
 
Fig No 02: Structure of Dalfampridine 
 
Chemical Formula  : C5H6N2 
Molecular Mass  : 94.1164 gm/mole 
Physical State  : Solid 
Colour   : Colourless 
Melting Point  : 155 to 158 °C 
Boiling Point   : 273 °C 
Solubility   :Water, polar organic solvents. 
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MECHANISAM OF ACTION 
Voltage-gated potassium channels represent open and close in response 
to changes in the transmembrane potential, and help regulate ionic potassium 
currents. Axons are progressively demyelinated which exposes potassium 
channels in multiple sclerosis. As a result, there is a leak of potassium ions 
which results in the repolarization of cells and a decrease in neuronal 
excitability. 
The overall impact is the impairment of neuromuscular transmission as 
it is harder to trigger an action potential. Despite characterization of 
dalfampridine a lipid-soluble compound that readily crosses the blood–brain 
barrier.The mechanism of action of dalfampridine has not been fully elucidated 
because the speciﬁc potassium channels that are blocked during therapeutic 
response have not been identiﬁed. However, the putative mechanism of action 
responsible for the therapeutic effects in MS is the restoration of conduction via 
blockade of the potassium channels that become exposed during demyelination. 
Dalfampridine act as a potassium channel blocker. Dalfampridine block to 
voltage-gated potassium channels which leads to prolong the action potential 
and in CNS to maintain the transmembrane potential. 
  Dalfampridine act to stimulate conduction in demyelinated axons that 
are exposed in MS patients.Dalfampridine facilitates neuromuscular and 
synaptic transmission by relieving conduction blocks in demyelinated axons in 
multiple sclerosis.MS patients who nonresponded to dalfampridine had an 
average increase in walking speed is approximately 25% lesser improvements 
than dalfampridine responders. 
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REVIEW OF LITERATURE  
 Corneliu C. Luca et al (2017) Studied that disease-related  
gait dysfunction causes extensive disability for persons with Parkinson's 
disease (PD), with no effective therapies currently available. The potassium 
channel blocker dalfampridine has been used in multiple neurological 
conditions and improves walking in persons with multiple sclerosis. D-ER is 
well tolerated in PD patients, however it did not show signiﬁcant beneﬁt for 
gait impairment (18). 
 Aakash Deep et al  (2016) revealed that Multiple sclerosis (MS) is a 
neurodegenerative disease of the central nervous system (CNS), causes 
irreversible disability in young adults but the cause and cure were unknown and 
it involves two arms and causes demyelination and neuro degeneration. Since, 
the treatment strategies for MS have increased rapidly but still proper 
knowledge regarding the nature of MS cleared the way for several more 
speciﬁc, more effective, and more comfortable therapies. Here, because of the 
stimulating recent developments about oral treatment for MS, the current state 
of approved and future therapy options were summarized here. In particular, 
we highlight oral treatment options in MS and it acts at the central and 
peripheral nervous systems, enhances conduction in demyelinated axons, and 
improves the walking ability of MS patients. Moreover number of clinical trials 
has evaluated the safety and efﬁcacy of fampridine in MS patients and it 
represents a major advance in symptomatic therapy for MS (19). 
 Ajay Kumara et al  (2016) A sensitive and selective HPLC method was 
developed for identification and quantification of five Potential genotoxic 
impurities (PGIs) viz. Impurity-I, Impurity-II, Impurity-III, Impurity IV and 
Impurity-V in Dalfampridine (Drug substance). The method utilizes Zorbax 
silica column (250 mm x 4.6 mm, 5.0 μm) with UV detector in HILIC 
(Hydrophilic Interaction Liquid Chromatography) mode for quantitation of five 
PGIs. It has been validated as per International Council for Harmonisation 
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(ICH) guidelines and is able to quantitate all PGIs at 75 ppm with respect to 20 
mg/mL of sample concentration. It is linear in the range of 22.5 , 112.5 ppm for 
all PGIs, which matches the range of LOQ-150% of estimated permitted level 
(75 ppm). Its accuracy was established in the range from 88.14-107.65% for 
these PGIs. The correlation coefficient of each impurity was >0.999. It is a 
good quality control tool for quantitation of PGIs in Dalfampridine at low level 
(20) 
 Poonam P. Patil et al  (2015) revealed that impurities are nothing but 
the unidentified, unintended substance present along with desired substance. 
The newer regulations of US FDA, MHRA intends for the requirements of 
impurities rather than purity of pharmaceuticals. The impurity profiling of 
pharmaceuticals can be done by using various analytical methods like UV, 
HPLC, LC-MS, GC-MS, SCFC etc. Mostly RP-HPLC method commonly 
adopted for the qualification as well as quantification of impurities. The present 
review is an attempt made in the respect of highlighting the some important 
methods, quality guidelines and applications of impurity profiling (21). 
 Angela Applebee et al (2015) Dalfampridine extended-release (ER) 
tablets 10 mg BID have been approved for use in improving walking in people 
with multiple sclerosis (MS). This subgroup analysis evaluated the effects of 
dalfampridine ER 5 and 10 mg BID on distance walked, as assessed using the 
6-minute walk (6MW) test. Effect was compared with standard and control 
placebo (22). 
 Alessandra Lugaresi et al   (2015) Studied that fampridine 10 mg twice 
daily, improves walking ability in approximately one-third and walking speed 
in about 25% of patients, independently from disease course, compared with 
placebo; it also improves leg strength. Treatment is generally well tolerated, 
although there is a dose-dependent increased risk of seizures, especially with 
dosages >10mg twice daily (23). 
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 Andrew R et al (2013) was developed to maintain drug plasma levels 
within an arrow therapeutic window and assessed for its ability to improve 
walking in MS. The putative mechanism of action of dalfampridine-ER is 
restoration of axonal conduction via blockade of the potassium channels that 
become exposed during axonal demyelination. Two pivotal phase III clinical 
trials demonstrated that dalfampridine-ER 10-mg tablets administered twice 
daily improved walking speed and patient-reported perceptions of walking in 
some patients. Dalfampridine-ER was generally well tolerated, and at the 
approved dose, risk of seizure was neither elevated relative to placebo nor 
higher than the rate in the MS population. Dalfampridine-ER was approved in 
the United States for the treatment of walking in patients with MS as 
demonstrated by an increase in walking speed. It is the ﬁrst pharmacologic 
therapy for this indication and has been incorporated into clinical management 
of MS (24). 
 Chunli Liu et al (2013) synthesised of substituted pyridines has drawn 
the attention of many chemists due to their importance as building blocks for 
biologically active compounds and materials. This mini-review focuses on 
recent developments relating to the synthesis of substituted pyridines from 
pyridine N-oxides, along with their interesting mechanism aspects. New 
developments including alkenylation, alkynylation, alkylation, arylation, 
amination and cyanation (25). 
 Jana Lizrova Preiningerova et al (2013) Prolonged-release fampridine 
is a potassium channel blocker that improves conductivity of signal on 
demyelinated axons in central nervous system. Fampridine PR has been 
approved to improve speed of walking in patients with multiple sclerosis. This 
statement provides a brief summary of data on fampridine PR and 
recommendations on practical use of the medication in clinical practice, 
prediction, and evaluation of response to treatment and patient management. A 
prolonged-release fampridine has been developed to improve the 
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pharmacokinetics and to reduce the side effects associated with IR-4AP. 
Fampridine PR has a reduced peak plasma levels and a prolonged half-life that 
allows administration every 12 h (26). 
 Patrick P et al  (2013) studied dalfampridine (Ampyra) is indicated to 
improve walking in patients with multiple sclerosis (MS) and was found to be 
effective in 35%, 43% of individuals with MS in clinical trials. Dalfampridine 
may increase seizure risk, particularly in patients with renal impairment. A 
U.S. managed care expert consensus panel agreed that patient access to 
dalfampridine is best managed by a prior authorization (PA) in accordance with 
the FDA-approved labeling. To ensure safe and appropriate dalfampridine use, 
a health plan developed and implemented a 2-phase point-of-sale PA program. 
The study indicates that a dalfampridine PA program potentially improved 
safety and minimized dalfampridine costs. A PA program is effective in 
selecting appropriate utilisers for initial theraphy. Addition of care management 
may further optimize use by encouraging adherence and tracking patient 
response (27). 
 Abolghasem Jouyban et al (2012) described the structural alerts to 
predict potential genotoxic activity for identiﬁed impurities is now well 
established. However, the concordance between such alerts and biologically 
relevant genotoxic potential could be highly imperfect. Structural alerts are 
defined as molecular functionalities that are known to cause toxicity, and their 
presence in a molecular structure alerts the investigator to the potential 
toxicities of the test chemical. In silico toxicology is the application of 
computer technologies to analyze existing data, model, and predict the 
toxicological activity of a substance. In sequence, toxicologically based 
QSARs are mathematical equations used as a predictive technique to estimate 
the toxicity of new chemicals (28). 
 King AM et al (2012) 4-Aminopyridine (4-AP) selectively blocks 
voltage-gated potassium channels, prolongs the action potential, increases 
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calcium influx, and subsequently, enhances interneuronal and neuromuscular 
synaptic transmission. This medication has been studied and used in many 
disease processes hallmarked by poor neuronal transmission in both the central 
and peripheral nervous systems including: multiple sclerosis (MS), spinal cord 
injuries (SCI), botulism, Lambert-Eaton syndrome, and myasthenia gravis. It 
has also been postulated as a potential treatment of verapamil toxicity and 
reversal agent for anesthesia-induced neuromuscular blockade. To date, there 
have been limited reports of either intentional or accidental 4-AP toxicity in 
humans. Both a case of a patient with 4-AP toxicity and review of the literature 
are discussed, highlighting commonalities observed in overdose (29). 
 Michael D et al (2012) studied Dalfampridine theoretically works to 
improve conduction and enhance walking by inhibiting potassium channels in 
the axonal membrane and by prolonging action potentials in demyelinated 
neurons. The efﬁcacy of dalfampridine has been reported in 2 Phase III clinical 
trials in patients with MS. When comparing dalfampridine 10 mg twice daily 
with placebo, these studies found a statistically signiﬁcant improvement in 
walking(42.9% vs9.3% and35% vs8%; P < 0.001). However, clinical trials and 
post marketing surveillance have found a statistically signiﬁcant increased risk 
of seizures with dalfampridine (30). 
 Masamitsu Honma et al (2012) described to Major Safety Issues of 
ICH Guideline for Genotoxic Impurities is DNA reactive substances which can 
be detected by Ames assay. Application of Threshold of Toxicological Concern 
(TTC) to control genotoxic impurities. Risk assessment for patients and healthy 
volunteers during clinical development. Evaluation of genotoxicity of 
impurities using the Structure Activity Relationship (SAR). Risk mitigation 
considering exposure duration and hazard characterization.DNA reactive 
substances that have a potential to directly cause DNA damage when present at 
low levels leading to mutations and therefore, potentially causing cancer. This 
type of mutagenic carcinogen is usually detected in a bacterial reverse mutation 
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assay. Non-mutagenic typically have threshold mechanisms and usually do not 
pose carcinogenic risk in humans at the level ordinarily present as impurities 
(31). 
 Renu Solanki et al (2012) studied Pharmaceuticals impurities are the 
unwanted chemicals that remain or are generated during the formulation of 
medicines. Impurity profiling helps in detection, identification and 
quantification of various types of impurities as well as residual solvents in bulk 
drugs and in pharmaceutical formulations. It is a best way to characterize 
quality and stability of bulk drugs and pharmaceutical formulations. ICH, 
USFDA, Canadian Drug and Health Agencies are emphasizing on the purity 
requirements and on identification of impurities in active pharmaceutical 
ingredients as presence of impurities even in small amounts may influence the 
efficacy and safety of the pharmaceutical products. Thus enlightening the need 
of impurity profiling of drug substances in pharmaceutical research this review 
focuses on various analytical methods for identification as well as 
quantification of impurities present in the pharmaceuticals (32). 
 Dunn J et al (2011) described that multiple sclerosis (MS) can cause 
progressive walking impairment that contributes to disability, loss of 
independence, and reduced quality of life. Dalfampridine a voltage-dependent 
potassium channel blocker, has been shown to improve walking in patients 
with MS, as demonstrated by an increase in walking speed. Voltage-gated 
potassium channels represent a family of related proteins that span cell 
membranes, open and close in response to changes in the transmembrane 
potential, and help regulate ionic potassium currents. The extended-release 
formulation of dalfampridine has been shown in clinical trials to improve 
walking speed in approximately one third of MS patients with ambulatory 
impairment. The putative mechanism of action of dalfampridine is restoration 
of action potential conduction via blockade of an as yet uncharacterized subset 
of potassium channels in demyelinated axons (33). 
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 Fabio Garavaglia et al (2011) A process for the preparation of  
Dalfampridine, starting from 4-pyridinecarbonitrile using a one-pot procedure 
said process is carried out with no need for isolating intermediates and is 
particularly advantageous as far as environment, yields, productivity and purity 
of the resulting product are concerned, both in the reaction mixture and in the 
isolated crystal (34). 
 Ayre1 A et al (2011) described impurity profiling is the process of 
acquiring and evaluating data that establishes biological safety of an individual 
impurity. Thus, revealing its need and scope in pharmaceutical research. There 
is no clear definition for impurity in the pharmaceutical world. Impurity 
profiling includes identification, structure elucidation and quantitative 
determination of impurities and degradation products in bulk drug materials 
and pharmaceutical formulations. Identification of impurities is done by variety 
of Chromatographic and Spectroscopic techniques, either alone or in 
combination with other techniques. The advent of hyphenated techniques has 
revolutionized impurity profiling, by not only separation but structural 
identification of impurities as well. The present review covers various aspects 
related to the analytical method development for impurity profiling of an active 
pharmaceutical ingredient (35). 
 FDA  (2008) The Food and Drug Administration (FDA) is announcing 
the availability of a draft guidance for industry entitled‘‘Genotoxic and 
Carcinogenic Impurities in Drug Substances and Products: Recommended 
Approaches.’’ This draft guidance is intended to inform pharmaceutical 
manufacturers of the agency’s thinking regarding genotoxic and carcinogenic 
impurities in drug substances and drug products, including biologic products 
that are regulated by the Center for Drug Evaluation and Research (CDER), 
and to provide recommendations on how to evaluate the safety of these 
impurities during clinical development and for marketing applications. This 
draft guidance, when finalized, will clarify FDA’s additional testing and 
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exposure threshold recommendations for situations in which genotoxic or 
carcinogenic impurities are present. This draft guidance addresses synthetic 
impurities and degradants in drug substances, but does not otherwise address 
the genotoxicity or carcinogenicity of actual drug substances or intended drug 
product ingredients. This draft guidance also applies to known starting 
materials or anticipated reaction products (36). 
 Sanjay B. Bari et al (2007) Described that ICH, USFDA, Canadian 
Drug and Health Agency are emphasizing on the purity requirements and the 
identification of impurities in Active Pharmaceutical Ingredient’s (API’s). 
Qualification of the impurities is the process of acquiring and evaluating data 
that establishes biological safety of an individual impurity. Conventional 
Liquid Chromatography, particularly, HPLC has been exploited widely in  field 
of impurity profiling; the wide range of detectors, and stationary phases along 
with its sensitivity and costeffective separation have attributed to its varied 
applications. Headspace GC is one of the most preferred techniques for 
identification of residual solvents. The advent of hyphenated techniques has 
revolutionized impurity profiling, by not only separation but structural 
identification of impurities as well (37). 
 Do B& Goulay et al  (2006) 3,4-Diaminopyridine is used to treat some 
symptoms met in Lambert Eaton myasthenia syndrome. It was shown efﬁcient 
to reduce a form of variable muscle weakness and fatigability typical of the 
disease and correlated to a block of acetylcholine release. A high performance 
liquid chromatographic method for the determination of 3,4-diaminopyridine in 
the presence of related substances and its degradation products is described. 
The method is based on the use of a C18 bonded phase column and a mobile 
phase composed of 10 volumes of acetonitrile and 90 volumes of an aqueous 
solution containing 1 g L)1 sodium octane sulfonate and 0.77 g L)1 ammonium 
acetate. The pH of the aqueous solution was adjusted to 1.9 with triﬂuoracetic 
acid. All peaks are eluted in <40 min. The method was demonstrated to be 
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precise, accurate and speciﬁc even though a major part of the drug is 
decomposed. The results indicate that the proposed method could be used in 
stability assays (38).        
 Hayes K.C et al (2004) studied that 4-AP is a potassium channel- 
blocker that enhances conduction in focally demyelinated axons, improves 
synaptic transmission and potentiates muscle contraction. This is the first drug 
approved in the United States by USFDA to improve walking in patients with 
multiple sclerosis and is chemically known as 4-aminopyridine.The 
pharmacokinetics and safety of sustained-release 4-aminopyridine, a potassium 
channel blocker, in subjects with chronic, incomplete spinal cord injury 
(SCI).In subjects with chronic, incomplete SCI, Fampridine-SR was slowly 
absorbed and eliminated, which will allow Fampridine-SR to be administered 
in a convenient twice-daily manner. Fampridine-SR was well tolerated at 
dosages from 25 to 60 mg twice daily (39). 
 Donnelly RF et al, (2004) Determined the chemical stability of 4-AP 
capsules containing 10 mg of active ingredient. Ten-milligram capsules were 
prepared from 4-AP obtained from 2 suppliers, with either lactose or 
microcrystalline. The hard gelatin capsules were stored in amber snap top 
prescription vials at room temperature (20°C to 25°C) with protection from 
light. Two capsules were collected from each group on days 0, 14, 28, 62, 96, 
125, 180, and 365 and stored in a rubber stoppered glass test tube containing 
desiccant material at 70°C.. Ten-milligram capsules of 4-AP, prepared from 
material obtained from each supplier and diluted with either lactose or 
microcrystalline cellulose, retained at least 94 % of the initial content for 365 
days when stored in plastic prescription vials at room temperature with 
protection from light. Extemporaneously prepared 10 mg capsules of 4-AP 
were considered stable for 365 days when stored in plastic prescription vials at 
room temperature with protection from light (40). 
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 Trisse L A et al (2002) Studied the chemical stability of 4 
aminopyridine 5-mg capsules and 3,4-diaminopyridine 5mg capsules under a 
variety of storage conditions. Each of the two drug preparations was 
extemporaneously prepared in hard gelatin capsules; lactose and micronized 
silica gel were used as excipients. Samples were stored under three conditions: 
refrigeration at 4°C and protected from light for 6 months, protected from light 
at room temperature that ranged from 22°C to 24°C for 6 months, and at a 
temperature of 37°C and protected from light for 1 month. Capsule content 
weight did not change during the study. Both 4-aminopyridine and 3,4-
diaminopyridine exhibited excellent chemical stability under all study 
conditions. Little or no loss of drug content occurred in either product under 
refrigeration, at room temperature, and even at the elevated temperature of 
37°C. The oral 5 mg capsules of 4-aminopyridine and 3,4-diaminopyridine did 
not undergo decomposition or other adverse changes within 6 months at 
refrigerated or room temperature or within 1 month of storage at 37°C (41).  
 Vladimir N. Bulavka et al (2000)  studied the reduction of 4-
nitropyridine-N-oxide with iron and aqueous mineral acids. The reduction with 
iron and hydrochloric acid gives mainly 4-aminopyridine (80-85%), and as by-
products 4aminopyridine-N-oxide, 4-pyridone, and 4,4’-azopyridine. The 
reduction with iron and 25-30% sulphuric acid proceeds slowly, but the yield 
of the desired 4-aminopyridine is better. The isolation of the reaction product 
after reduction, subsequent neutralization with sodium carbonate, and filtration 
was carried out by two methods. The first method was extraction with ethyl 
acetate. After removal of the solvent 4aminopyridine was obtained in 85-90% 
yield. The second method was the concentration of the filtrate on the rotatory 
evaporator, extraction with ethanol, and after evaporation of ethanol 
reextraction with hot benzene to give a title compound after cooling (85%). 
After evaporation of the solvent, crude 4-aminopyridine, if desired, was 
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acetylated with acetic anhydride to produce 4-acetylaminopyridine in 80-85% 
yield (42). 
 Choquet D et al (1992) Studied the mechanism by which 4-
aminopyridine blocks the delayed rectifier type potassium (K+) channels 
present on lipopolysaccharide activated murine B lymphocytes was 
investigated using whole-cell and single channel patch clamp recordings. 4-AP, 
was super fused for 3-4 min before applying depolarizing pulses to activate the 
channel. During the first pulse after application of 4-AP above 50 M, the 
current inactivated faster, as compared with the control, but its peak was only 
reduced at high concentrations of 4-AP (Kd = 3.1 mM). After washing out the 
drug, the current elicited by the first voltage step was still markedly reduced, as 
compared with the control one, and displayed very slow activation and 
inactivation kinetics; this suggests that the K+ channels move from a blocked 
to an unblocked state slowly during the depolarizing pulse (43). 
 Casteel SW, BR. Thomas et al (1990) Determined appropriate 
diagnostic samples in acute poisoning cases. Tissues from rats dosed with 
4aminopyridine were extracted with methylene chloride. Extracts were 
analyzed by high performance liquid chromatography using an isocratic solvent 
system of acetonitrile and aqueous solution (15 : 85 v/v) consisting of 0.015 M 
sodium salt of 1-heptane-sulfonic acid, 0.002 M tetra methyl ammonium 
bromide, and 0.01 M sodium di-hydrogen phosphate adjusted to pH 3.0 with 
phosphoric acid (44). 
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AIM AND OBJECTIVES 
4-Aminopyridines are important intermediates for chemicals, 
pharmaceuticals and agrochemical industry. Several 4-aminopyridine 
derivatives are known to be important intermediates for the preparation of 
various herbicides, antibacterial, antiviral drugs and dyes. For example, 4-
aminopyridine, as fampridine, is used for the treatment of multiple 
sclerosis. It has been found that fampridine improve impulse conduction in 
nerve fibers in which the insulating layer, called myelin, has been 
damaged. 4-Aminopyridine is also used as an intermediate for 
antineoplastic, anticoagulant, anti-inflammatory, antispasmodic and 
antiasthmatic drugs and as additives for foodstuffs. 3 - aminopyridine and 
2-aminopyridine derivatives are used as an intermediate for fungicides, 
herbicides and several drugs. 
Dalfampridine used for the treatment of multiple sclerosis so, the 
drug availability in the finished dosage form is very important, owing the 
importance of drug availability the percentage of impurities should be 
within the limit as per ICH guidelines. International Conference on 
Harmonization (ICH) formulated guidelines regarding the control of 
impurities.  Various regulatory authorities like ICH, USFDA, Canadian 
Drug and Health Agency are emphasizing on the purity requirements and 
the identification of impurities in Active Pharmaceutical Ingredient’s 
(API’s).  
Importance is drawn to identify and characterize the level of  
genotoxic impurities in dalfampridine, the present study was aimed to 
perform identification, synthesis and characterization and biological 
evaluvation of genotoxic dalfampridine impurities and its characterization 
done by the analytical techniques such as the LC-MS, HPLC, and NMR 
spectroscopy. Finally evaluvation of its anti bacterial activity done by 
using agar well diffusion method with some bacterial strains.  
Aim and Objectives  
Page 28 
OBJECTIVES 
 
Hence the main objectives of present project are: 
01. To Synthesize the targeted molecules 
02. To Characterize synthesized molecules by the LC-MS spectroscopy 
03. To achieve highly pure impurities by Purification of the synthesized 
molecule by chromatographic techniques like column and automated 
combi flash. 
04. Analysis of products by HPLC for its purity  
05. Product confirmation by the NMR spectroscopy. 
06. Evaluvation of anti bacterial activity by using agar well diffusion 
method. 
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PLAN OF WORK 
MATERIAL & METHODS 
 All the chemicals used for current work were laboratory Grade and 
purchased from approved vendors. 
 All reactions were carried out in dry glassware under an atmosphere of 
dry nitrogen. 
 Glass wares used for all the reactions were of borosilicate quality. 
 Rotavapor-B.U.CHI is a device used in R&D for the efficient and 
removal of solvents from samples by evaporation 
 All the reactions every step were monitored by using thin layer 
chromatography. 
 The suitable mobile phases (solvent system for TLC) as applicable were 
developed using silica Gel-G ready plates. Pre-coated aluminium silica 
plates were used with suitable mobile phase. 
 Progress of Reaction and monitoring for each stage is performing by 
LCMS. 
 Mass of all synthesized compounds can be determined by using 
Thermo- DSQ-Trace and Advantage Max, Agilent 6130 LC/MS single 
quad mass spectrometer. 
 Separation and purification of synthesized impurities carried out by 
using column chromatography and automated chromatography COMBI 
FLASH Rf device.  
 The purity of all synthesized compounds identified by HPLC Agilent-
1200 with PDA detector. 
 Melting points for synthesized molecules were recorded by METTLER 
TOLEDO apparatus. 
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 All the proton NMR spectra by using Varian Mercury NMR 
Spectrophotometer at 400MHz frequency at PADM Laboratory. The 
solvent used to record was CDCl3 and DMSO. 
 All the compounds considered for biological evaluation were prepared 
by standard methods as outlined in scheme. 
 The media used for biological evaluation was purchased from Hi Media 
and media were prepared according to manual. 
 Biological evaluation was done under Laminar Air Flow. 
 The biological evolutions for all synthesized compounds were carried 
out at J.K.K. Nattraja College of Pharmacy. 
 
SEPERATION AND PURIFICATION: 
 The separation of Dalfampridine and its potential genotoxic impurities 
was critical because of similar polarity and chemical structures. Baseline 
separation of impurities and Dalfampridine were given the priority. 
 Teledyne ISCO has developed this advance automated chromatography 
Combi Flash Rf system that uses RFID (Radio Frequency Identification) 
technology. This system can automatically set the parameters for purification 
runs and fraction collection. 
 Separartion was performed by using CHROMABOND FLASH RS-40 
SiOH 40-63 micron prepacked catridges (columns) 
 
IDENTIFICATION AND CHARACTERISATION 
 Synthesized potential genotoxic impurities were identified and 
characterized by following methods such as:  
 TLC-Thin layer chromatography 
 LCMS-MS spectroscopy 
 HPLC-High Performance liquid chromatography 
 H-NMR-proton nuclear magnetic resonance spectroscopy 
 Melting point determination. 
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Thin layer chromatography:  
 TLC is a technique in which the stationary phase is a subdivided solid 
and which is spread over on aluminium rigid plate. A liquid i.e. mobile phase is 
allowed to move above the surface of the plate. This technique is normally used 
for the identification of the organic compounds with variable Rf values. The 
same method is also applied to study the progress of the reaction during onsite 
monitoring and to confirm the approximate purity of the desired product. 
 Pre-coated aluminium silica plates were used with suitable mobile 
phase. Once after TLC development the spots were observed and detected by 
placing the developed TLC plate in UV cabinet. 
 
Mass spectroscopy:  
 The mass spectroscopy technique is useful to provide information 
regarding the atomic and molecular weight, structure of the compound, its 
mechanism, kinetic study of the reaction and the mixture analysis. The mass 
technique involves bombarding the electrons and converted to highly energetic 
molecular ions are also called positively charged ions, that can be easily break 
up into their smaller ions (fragment ions) and sorting them in gas phase, spectra 
is obtained according to mass/charge ratio. The Mass spectra of all synthesized 
compounds were carried out in Thermo- DSQ-Trace and Advantage Max, 
Agilent 6130 LC-MS single quad mass spectrometer.  
 
HPLC spectroscopy: 
 The HPLC method is useful to identify the purity of all synthesized 
compounds with its different retention times helps to confirm the product from 
raw material or starting compounds. The HPLC for all compounds were carried 
out in Agilent-1200 with PDA detector. 
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Nuclear magnetic resonance spectroscopy:  
 The interaction between molecule and applied electromagnetic forces is 
observed by subjecting a molecule simultaneously to two magnetic forces, one 
is stationary and other variable radio frequency. At a combination of 
electromagnetic fields some of the energy is absorbed by the molecule and 
absorption of the electromagnetic field was observed as a change in signals 
developed by the radio frequency detector. This technique is useful in detecting 
the structure of the molecule. The NMR spectra for the synthesized compounds 
were recorded out in Varian Mercury NMR Spectrophotometer and Agilent at 
400MHz frequency. Varien software used to record the spectrum, named as 
“Vnmr J” 3.2 version which is supported by Lynux Red Hat.  The solvent used 
to record was CDCl3 and DMSO. 
 
Melting point determination:  
 Melting point determination of a compound is one way to test if the 
substance is pure or impure. Melting point study is the one of the valuable 
criteria for purity determination of  an organic compounds. The pure crystalline 
compound will be having definite and sharp melting point. The melting point 
for all the newly synthesized molecules were carried out using METTLER 
TOLEDO melting point apparatus. 
 
SYNTHESIZING PLAN FOR DALFAMPRIDINE GENOTOXIC 
IMPURITIES: 
Dalfampridine Genotoxic impurities listed in United States 
Pharmacopoeia (45) and few potential and non pharmacopoeial impurities were 
selected for the synthesis as per the literature review and listed below. 
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S. 
NO 
IMPURITY 
CODE CHEMICAL NAME STRUCTURE 
1. IMP - DAL 1 1,2-Di(pyridine-4-yl) hydrazine 
N
NHN
NH
 
2. IMP – DAL 2 4-Aminopyridine-N-oxide NH2N O
 
3. IMP – DAL 3 2-Aminopyridine N
NH2
 
4. IMP – DAL 4 3-Aminopyridine 
N
NH2
 
5. IMP – DAL 5 Pyridine-4-carboxamide 
N
O NH2
 
6. IMP – DAL 6 Pyridine-4-carboxylic acid 
N
O OH
 
7. IMP – DAL 7 (1, 3-Di (pyridin-4-yl) urea N
H
O
N
H
NN
 
 
 
Table No 04:  Plan to synthesis of Dalfampridine impurities 
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METHODOLOGY  
SCHEME TO SYNTHESIS IMP-DAL 1 (1,2-di(pyridin-4-yl)hydrazine): 
N
pyridine
N
O
N
O
NO2
N
O
N
O
N N
NH2NH2.H2O/EtOH
N
N N
N
RT
N
HN NH
N
HNO3/H2SO4H2O2/AcOH
120 oC, 3h
SnCl2/Aq. NaOHReflux, 2h
RT
Raney nickel/H2
N- Oxidation
Nitration
Azo Coupling
Deoxigenation
Reduction
C5H5N
Mol. Wt.: 79.1
Step 1
C5H5NO
Mol. Wt.: 95.1
C5H4N2O3
Step 2
Step 3
Step 4
Step 5
C10H8N4O2
Mol. Wt.: 216.2
C10H8N4
Mol. Wt.: 184.2
C10H10N4
Mol. Wt.: 186.21
 
 
Fig No 03:   Synthetic scheme of IMP-DAL 1. (1, 2-di(pyridin-4-yl)hydrazine). 
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STEP 1: Oxidation of Pyridine: 
N
Pyridine
N
O
H2O2/AcOH
N-Oxidation
C5H5N
Mol. Wt.: 79.1 C5H5NO
Mol. Wt.: 95.1
Step 1
 
Fig No 04: Step 1 Oxidation of IMP-DAL 1 
Pyridine is oxidized into pyridine N oxide which on treatment with  H2O2/ 
AcOH.10 grams of Pyridine was taken in the single neck RB flask, to this 30 
ml of acetic acid was added and stirred for ten minutes. 50 ml of hydrogen 
peroxide was added and closed the flask with stopper. The reaction mixture 
was stirred over night. 
 
Workup: 
 After completion of the reaction, removed the excess acetic acid and 
peroxide by concentrating in the rotavapor and dried completely. Three times 
added a toluene and removed the solvent in rotavapor to expel the traces of 
water. Product Yield is 10 gm. 
 
STEP 2:  Nitration of Pyridine N- Oxide: 
N
O
N
O
NO2
HNO3/H2SO4
120 oC, 3h
Nitration
Step 2
C5H5NO
Mol. Wt.: 95.1
C5H4N2O3
Mol. Wt.: 140.1  
Fig No 05:  Step 2 Nitration of IMP-DAL 1 
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Preparation of the nitrating mixture: 
 10ml of fuming HNO3 are filled in a 250 mL round bottom flask with 
magnetic stir bar. Slowly and in portions 10ml of conc. H2SO4 are added under 
stirring and cooling in an ice bath. The nitrating mixture is brought to a 
temperature of 20 °C. 
 10gms of pyridine-N-oxide are filled in the reaction flask and heated to 
60°C. The nitrating mixture is transferred into an addition funnel and added 
drop wise within 30 minutes under stirring without further heating. Thereby the 
internal temperature drops to about 40°C. Afterwards the reaction mixture is 
refluxed for 3 hours to 125-130°C internal temperature. 
 
Work up: 
 After cooling down to room temperature the reaction mixture is poured 
in a 1 L beaker containing 150g finely crunched ice. Then about 170 mL of a 
saturated sodium bicarbonate solution are added carefully in portions until a 
pH-value of 7 - 8 is reached. A yellow crystalline solid precipitates, consisting 
of product and sodium sulfate. Crude yield is 5.5 gm.  
 To the yellow crude product acetone is added and the insoluble white 
salt is separated over a Buechner funnel. The solvent is evaporated from the 
filtrate at a rotary evaporator, the remaining yellow product is dried in a 
desiccator.  Product Yield is 3.5 gm.  
 
STEP 3: Azo Coupling of 4-Nitro Pyridine N- Oxide: 
N
O
NO2
N
O
N
O
N N
SnCl2/Aq. NaOH
Reflux, 2h
Azo Coupling
C5H4N2O3
Mol. Wt.: 140.1
C10H8N4O2
Mol. Wt.: 216.2
Step 3
 
Fig No 06: Step 3 Azo Coupling of IMP-DAL 1 
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 Three-neck round-bottomed flask, fitted with a stirrer and a reflux 
condenser, is placed on a steam cone. In the flask are placed 3.5 gm of 4-nitro 
pyridine -N- oxide is dissolved in 200 ml of 10% Aq. NaOH . To the mixture is 
added 10 gm of SnCl2, the stirrer is started, and the mixture is refluxed for 1 
hour at 100°C. The initial addition of the reactants resulted in a cloudy yellow 
solution with a black deposit on the bottom of the flask (metallic tin). At the 
end of two hours, the solution was a vivid red with dark red oil on the surface. 
 
Workup:  
 The reaction mass was concentrated by removing sodium hydroxide. 
The reaction mass quenched in 20 ml of water and extracted with 100 ml of 
DCM and concentrated. Product Yield is 2gm.  
 
STEP 4: Deoxygenation: 
N
N N
N
RT
Raney nickel/H2
Deoxigenation
N
O
N
O
N N
Step 4
C10H8N4O2
Mol. Wt.: 216.2
C10H8N4
Mol. Wt.: 184.2
 
Fig No 07:  Step 4 Deoxygenation of IMP-DAL 1 
 
 The catalytic reduction over Raney nickel at atmospheric temperature 
and pressure was suitable for this reaction. The catalytic reduction of 2gm of 
step 3 product in 100 ml of MeOH, with 1 mole equivalent of Raney nickel 
added. The reaction is carried under hydrogen pressure. The reaction is stopped 
after 3-4 hrs reduction. The reaction is monitored by TLC and LC-MS. 
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Workup: 
 The reaction mass is filtered off by using high vacuum remove Raney 
nickel. The filtrate is concentrated to remove methanol by using rotary 
evaporator. Product Yield is 1.5 gm. 
 
 STEP 5: Reduction: 
NH2NH2.H2O/EtOH
N
N N
N N
HN NH
N
RT
Reduction
Step 5
C10H8N4
Mol. Wt.: 184.2
C10H10N4
Mol. Wt.: 186.21
 
 
Fig No 08:  Step 5 Reduction of IMP-DAL 1 
 
 1.5gms of step 4 product was dissolved in 30 ml of ethanol and 0.3ml of 
hydrazine hydrate was added. The reaction was carried out to color change 
from deep orange to brown color. The reaction mass was monitored by TLC 
and LC-MS. 
 
Workup: 
 The  reaction mass was concentrated by removing ethanol and unreacted 
hydrazine hydrate .The reaction mass quenched in 20 ml of water and extracted 
with 100 ml of DCM and concentrated.  Product Yield is1gm. 
 Synthesized final mass of the compound was separated and purified by 
automated combiflash RF and purity of compound is analyzed by HPLC. 
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SCHEME TO SYNTHESIS IMP-DAL 2 (4- Amino pyridine N- Oxide) 
N
N
O
N
NH2
O
HNO3/H2SO4
Pd-C/H2
Methanol/RT
H2O2/AcOH
N-Oxidation
Pyridine N- Oxide
Pyridine
N
NO2
O
120 oC, 3h
Nitration
Reduction
C5H5N
Mol. Wt.: 79.1 C5H5NO
Mol. Wt.: 95.1 C5H4N2O3
Mol. Wt.: 140.1
C5H6N2O
Mol. Wt.: 110.11
Step 1 Step 2
Step 3
 
Fig No 09: Synthetic Scheme of IMP-DAL 2 (4- Amino Pyridine N- Oxide).  
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STEP 1: Oxidation of Pyridine: 
N
Pyridine
N
O
H2O2/AcOH
N-Oxidation
C5H5N
Mol. Wt.: 79.1 C5H5NO
Mol. Wt.: 95.1
Step 1
 
Fig No 10:  Step 1 Oxidation of IMP-DAL 2   
 
 Pyridine is oxidized into pyridine N oxide which on treatment with  
H2O2/ AcOH.10 grams of Pyridine was taken in the single neck RB flask, to 
this 30 ml of acetic acid was added and stirred for ten minutes. 50 ml of  
hydrogen peroxide was added and closed the flask with stopper. The reaction 
mixture was stirred over night. 
 
Workup: 
 After completion of the reaction, removed the excess acetic acid and 
peroxide by concentraring in the rotavapor and dried completely. Three times 
added a toluene and removed the solvent in rotavapor to expel the traces of 
water.  Product Yield is 10 gm. 
 
STEP 2: Nitration Of Pyridine N – Oxide: 
N
O
N
O
NO2
HNO3/H2SO4
120 oC, 3h
Nitration
Step 2
C5H5NO
Mol. Wt.: 95.1
C5H4N2O3
Mol. Wt.: 140.1  
Fig No 11: Step 2 Nitration of IMP-DAL 2 
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Preparation of the nitrating mixture: 10ml of fuming HNO3 are filled in a 
250 mL round bottom flask with magnetic stir bar. Slowly and in portions 10ml 
of conc. H2SO4 are added under stirring and cooling in an ice bath. The 
nitrating mixture is brought to a temperature of 20 °C. 
 10gms of  pyridine-N-oxide are filled in the reaction flask and heated to 
60°C. The nitrating mixture is transferred into an addition funnel and added 
dropwise within 30 minutes under stirring without further heating. Thereby the 
internal temperature drops to about 40°C. Afterwards the reaction mixture is 
refluxed for 3 hours to 125-130°C internal temperature. 
 
Work up  
 After cooling down to room temperature the reaction mixture is poured 
in a 1 L beaker containing 150g finely crunched ice. Then about 170 mL of a 
saturated sodium bicarbonate solution are added carefully in portions until a 
pH-value of 7 - 8 is reached. A yellow crystalline solid precipitates, consisting 
of product and sodium sulfate. Crude yield: 5.5 g  
 To the yellow crude product acetone is added and the insoluble white 
salt is separated over a Buechner funnel. The solvent is evaporated from the 
filtrate at a rotary evaporator, the remaining yellow product is dried in a 
desiccator.  Product Yield is 3.5 g.  
 
STEP 3: Reduction: 
N
NH2
O
Pd-C/H2
Methanol/RT
N
NO2
O
Reduction
C5H4N2O3
Mol. Wt.: 140.1
C5H6N2O
Mol. Wt.: 110.11
Step 3
 
Fig No 12:  Step 3 Reduction of IMP-DAL 2 
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 Nitro group rapidly reduced at room temperature to amino group in 
methanol in the presence of 10% palladium on carbon. 0.5gm of 4-nitro 
pyridine -N- oxide was dissolved in 30 ml of methanol .100 mg of 10% 
palladium added in that reaction mass. After added palladium the reaction mass 
carried under hyderogen pressure condition for overnight. The reaction is 
monitored by TLC and LC-MS.  
 
Workup 
 The reaction mass is filtered off by using high vacuum to remove 
palladium. The filterate is concentrated to remove methanol by using rotary 
evaporator.Yield:190 mg 
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SCHEME TO SYNTHESIS IMP-DAL 3 (2 – Amino pyridine) 
N
NH2
N
NO2
Zn / HCO2NH4
MeOH, RT
2- Nitro Pyridine 2- Amino Pyridine
REDUCTION
C5H4N2O2
Mol. Wt.: 124.1
C5H6N2
Mol. Wt.: 94.11  
Fig No 13:  Synthetic Scheme of IMP-DAL 3  
 
Reduction: 
 Nitro group rapidly reduced at room temperature to amino group in 
methanol in the presence of zinc and ammonium formate . 1gm of 2-nitro 
pyridine was dissolved in 20 ml of methanol. 0.5gm of ammonium formate and 
100mg of zinc added in that reaction mass at room temperature. After added 
zinc the reaction mass carried for overnight. The reaction is monitored by TLC 
and LC-MS.  
 
Workup 
 The reaction mass is filtered off by using high vacuum to remove zinc. 
The filterate is concentrated to remove methanol and unreacted ammonium 
formate  by using rotary evaporator. Product Yield is 0.6gm. 
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SCHEME TO SYNTHESIS IMP-DAL 4 (3 – Amino pyridine) 
NN
NO2 NH2
Zn/HCO2NH4
MeOH, RT
3- Nitro Pyridine 3- Amino Pyridine
REDUCTION
C5H4N2O2
Mol. Wt.: 124.1
C5H6N2
Mol. Wt.: 94.11  
Fig No 14:  Synthetic Scheme of IMP-DAL 4 
 
Reduction: 
 Nitro group rapidly reduced at room temperature to amino group in 
methanol in the presence of zinc and ammonium formate. 1gm of 3-nitro 
pyridine was dissolved in 30 ml of methanol. 0.5gm of ammonium formate and 
50mg of zinc added in that reaction mass at room temperature. After added zinc 
the reaction mass carried for overnight. The reaction is monitored by TLC and 
LC-MS.  
 
Workup 
 The reaction mass is filtered off by using high vacuum to remove zinc. 
The filterate is concentrated to remove methanol and unreacted ammonium 
formate  by using rotary evaporator.  
Product Yield is 0.5 gm. 
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SCHEME TO SYNTHESIS IMP-DAL 5 (Pyridine 4 - Carboxamide)  
N
HO O
SOCl2/THF
65 oC, 2h
N
Cl O
Aq. NH3
RT
Isonicotinic Acid
Chlorination
Isonicotinoyl chloride
N
H2N O
Isonicotinamide
Amination
Step 1 Step 2
C6H5NO2
Mol. Wt.: 123.11
C6H4ClNO
Mol. Wt.: 141.56
C6H6N2O
Mol. Wt.: 122.12
 
Fig No 15: Synthetic Scheme of IMP-DAL 5  
 
STEP 1: Chlorination of  Pyridine 4 – Carboxylic acid: 
N
HO O
SOCl2/THF
65 oC, 2h
N
Cl O
Isonicotinic Acid
Chlorination
Isonicotinoyl chloride
Step 1
C6H5NO2
Mol. Wt.: 123.11
C6H4ClNO
Mol. Wt.: 141.56  
Fig No 16:  Step 1 Chlorination of IMP-DAL 5 
 
1gm of isonicotinic acid was dissolved in 30ml of tetrahydrocarbon was 
taken in the single neck RB flask, to this add 5 ml of thionyl chloride. After 
added thionyl chloride the reaction mixture was refluxed for 2 hours to 65oc. 
The reaction is monitored by TLC and LC-MS. 
 
Workup 
 The reaction mass was concentrated by removing sodium tetra 
hydrofuran. The reaction mass quenched in 20 ml of water , neutralized by  
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saturated sodium bicarbonate and extracted with 100 ml of DCM and 
concentrated. Product Yield is 0.5gm 
 
STEP 2: Amination: 
N
Cl O
Aq. NH3
RT
Isonicotinoyl chloride
N
H2N O
Isonicotinamide
Amination
Step 2
C6H4ClNO
Mol. Wt.: 141.56
C6H6N2O
Mol. Wt.: 122.12  
Fig No 17: Step 2 Amination of IMP-DAL 5 
 
  The step one 0.5gm of product was dissolved in 30 ml of aqueous 
ammonia kept in a overnight. The reaction is monitored by TLC and LC-MS. 
 
Workup 
 After completion of the reaction, the excess ammonia was removed by 
concentrating in the rotavapor and dried completely. Product Yield is 0.4gm. 
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SCHEME TO SYNTHESIS IMP-DAL 6 (Pyridine 4 – Carboxylic acid)  
N
HO O
N
CH3
SeO2/Diphenyether
185 oC, 30 min
Isonicotinic Acid4-methylpyridine
C6H7N
Mol. Wt.: 93.13
C6H5NO2
Mol. Wt.: 123.11
 
Fig No 18:  Synthetic Scheme of IMP-DAL 6 
 
Oxidation of 4 – Methyl Pyridine : 
 0.5gm of 4-methyl pyridine placed in a three neck RB fitted with 
condenser and dissolved in 150ml of di-phenyl ether. The solution was heated 
up to 150°C. After reaching that heat 10 gm of selenium dioxide was added 
portion wise over a period of 15mins.The reaction temperature was raised up to 
185°C for 30 mins and end of the reaction precipitation is formed. 
 
Workup 
 After completion of reaction diphenyl ether was decanted from the 
precipitated selenium iso nicotinic acid residue. The residue was washed with 
75ml of low boiling ligroin. 
 The black selenium acid residue was ground to the powder and extracted 
with 100ml of boiling water. The fractions were formed and cooled in ice bath, 
rapidly crystals of iso nicotinic acid formed.  Product Yield is 0.48gm.    
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SCHEME TO SYNTHESIS IMP-DAL 7 (1,3 di (pyridine- 4 -yl) urea)  
Reflux, 3h
N
N
H
N
H
N O
CDI/Toluene
NH2
N
1,3-di(pyridin-4-yl)urea4- Amino Pyridine
C11H10N4O
Mol. Wt.: 214.22
C5H6N2
Mol. Wt.: 94.11  
Fig No 19:  Synthetic Scheme of IMP-DAL 7 
 
 500mg of 4-Aminopyridine was taken in the single neck RB flask, to 
this 30 ml of  toluene was added and stirred for ten minutes. To the mixture is 
added 0.7gm of 1,1’carbonyl di-imidazole and the mixture is refluxed for 3 
hours at 120°C.The reaction is monitored by TLC. 
 
Workup 
 The reaction mass was concentrated to removing toluene by rotary 
evaporator and the crude product was recrystallised from hexane wash and 
diethyl ether.  Product Yield is 0.2gm.  
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LC-MS INSTRUMENT & CHROMATOGRAPHIC DETAILS FOR 
CHARACTERISATION STUDY 
Equipment Details: 
LC - Agilent technologies - 1200 Series. 
MS - Agilent technologies - 6130 Quadrupole LC/MS. 
 
Chemicals and Reagents: 
Formic acid : AR grade 
Acetonitrile : HPLC grade 
Methanol : HPLC grade 
Ethanol : HPLC grade 
Water : Milli-Q 
 
Chromatographic Condition: 
Column description : C18 3.5µm, 4.6x100mm 
Column temperature: 30o 
Flow rate : 0.6ml/Minute 
Wavelength: 254 nm 
Injection volume: 20µm 
Runtime: 10 Minutes 
 
Gradient method details:  
Time Solv.  B Solv. C Solv. D Flow Pressure 
0.00 95.0 0.0 0.0 0.600 400 
4.00 5.0 0.0 0.0 0.600 400 
7.00 5.0 0.0 0.0 0.600 400 
7.10 95.0 0.0 0.0 0.600 400 
10.00 95.0 0.0 0.0 0.600 400 
Table No  05 : LC-MS gradient details  
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Lamp: UV Lamp 
Detector: DAD   
MS Conditions 
Method spray chamber: MM-ES+APCI 
 Positive Negative 
Capillary Voltage(V) 4000 2500 
Corona Current(µA) 10.0 10.0 
Charging Voltage(V) 2000 2000 
 
 Actual Set point Maximum 
Drying gas flow (1/min) 12.0 12.0 13.0 
Nebulizer pressure (psig) 35.0 35.0 60.0 
Drying gas 
temperature(oC) 249.0 250.0 250.0 
Vaporizer 
temperature(oC) 200 200.0 250.0 
Table No 06 : MS Conditions of Dalfampridine 
 
Solution preparation: 
Moble phase A [ 0.1% formic acid buffer] 
Add 1 ml of formic acid to 1000 ml of water , mix well and sonicate for 10 
mins. 
Mobile phase B [100 % acetonitrile]. 
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HPLC INSTRUMENT & CHROMATOGRAPHIC DETAILS FOR 
CHARACTERISATION STUDY 
 
Equipment Details: 
HPLC – Agilent technologies -1100 series 
Chemicals and Reagents: 
Formic acid : AR grade 
Acetonitrile : HPLC grade 
Water : Milli-Q 
CHROMATOGRAPHIC METHOD:  CNX- LC 
Chromatographic Condition:  
Column description : C18 3.5µm, 4.6x100mm 
Column temperature: 25o C 
Flow rate : 0.6ml/Minute 
Wavelength: 254 nm 
Injection volume: 20µl 
Runtime: 10 Minutes 
Gradient method details:  
Time Solv.  B Solv. C Solv. D Flow Pressure 
0.00 95.0 0.0 0.0 0.600 400 
4.00 5.0 0.0 0.0 0.600 400 
7.00 5.0 0.0 0.0 0.600 400 
7.10 95.0 0.0 0.0 0.600 400 
10.00 95.0 0.0 0.0 0.600 400 
Table No 07 : HPLC Gradient Method Details For CNX- LC 
Solution preparation: 
Moble phase A [ 0.1% formic acid buffer] 
Add 1 ml of formic acid to 1000 ml of water , mix well and sonicate for 10 
mins. 
Mobile phase B [100 % acetonitrile] 
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CHROMATOGRAPHIC METHOD:  CNX 
 
Chromatographic Condition: 
Column description : Shodex C 18 4 D 5 µm 
Column temperature: 25o C 
Flow rate : 0.8ml/Minute 
Wavelength: 254 nm 
Injection volume: 5µl 
Runtime: 35 Minutes 
 
Gradient method details:  
Time Flow(ml/min) %A %B %C %D Max Pressure (bar) 
5.00 0.800 50.00 50.00 0.00 0.00 400 
20.00 0.800 40.00 60.00 0.00 0.00 400 
25.00 0.800 30.00 70.00 0.00 0.00 400 
25.00 0.800 70.00 30.00 0.00 0.00 400 
35.00 0.800 70.00 30.00 0.00 0.00 400 
Table No 08 : HPLC Gradient Method Details For CNX 
Solution preparation: 
Moble phase A [ 0.1% formic acid buffer] 
Add 1 ml of formic acid to 1000 ml of water , mix well and sonicate for 10 
mins. 
Mobile phase B [100 % acetonitrile] 
 
  
Methodology 
Page 53 
CHROMATOGRAPHIC METHOD:  DALFAMPRIDINE 
 
Chromatographic Condition: 
Column description : Shodex C 18 4 D 5 µm 
Column temperature: 30o C 
Flow rate : 2ml/Minute 
Wavelength: 275 nm 
Injection volume: 10µl 
Runtime: 25 Minutes 
Gradient method details:  
Time Flow(ml/min) %A %B %C %D Max Pressure (bar) 
0.00 2.00 90.00 10.00 0.00 0.00 400 
5.00 2.00 80.00 20.00 0.00 0.00 400 
15.00 2.00 80.00 20.00 0.00 0.00 400 
20.00 2.00 90.00 10.00 0.00 0.00 400 
25.00 2.00 90.00 10.00 0.00 0.00 400 
Table No 09 : HPLC Gradient Method Details For Dalfampridine 
 
Solution preparation  
Mobile phase A : 3.03 g/l of sodium 1-heptanesulfonate, 1.36 g/l of monobasic 
potassium phosphate, and 1.15 g/l of phosphoric acid in water. 
Mobile phase B : 100% Acetonitrile 
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AUTOMATED COMBI FLASH INSTRUMENT AND 
CHROMATOGRAPHIC  ITS DETAILS FOR PURIFICATION 
 
Equipment:   
Combi flash Rf 200 
Chemicals and reagents : 
Methanol 
DCM 
Ethyl acetate 
Hexane 
Chromatographic Condition: 
Column description : iLOK – 40g (70 ml) 1 D 26.8 x H127  
Column temperature: 25o C 
Flow rate : 30ml/Minute1 
Wavelength: 210 nm, 254 nm 
Runtime: 60 Minutes 
Solvent system: 
Moble phase A [ 80 % DCM] 
Mobile phase B [20 % Methanol] 
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EVALUATION OF ANTI BACTERIAL ACTIVITY 
 The condition which must be fulfilled before screening the antibacterial 
activity. The organism and drug substance to be evaluated should be contacted 
intimately. The microorganism’s growth should be maintained under 
conditions like incubation period, temperature, nutrient media, etc. Throughout 
the study conditions were maintained. Sterile environment should be 
maintained. Several researchers reported different method for evaluation of 
antibacterial activity. Few of the widely used method were as follows, 
1. Agar-streak dilution method 
2. Serial-dilution method 
3. Agar-diffusion method 
 
 From above mentioned technique agar diffusion method was used for 
screening of antibacterial activity which is described as follows, 
 
Agar Diffusion Method 
Following are the techniques which were used for agar diffusion method 
1. Agarcup 
2. Agarditch  
3. Paperdisc 
 
 For our study, we used the first method, to assess the minimum 
inhibitory concentration (MIC). 
 Non-automated invitro bacterial tests.  This method gives accurate, 
precise results to identify the antimicrobial agent which is required to inhibit 
the growth of precise microorganisms. 
 
Identification of MIC (Minimal Inhibitory Concentration) by using agar 
cup method 
1. All novel synthesized molecules were tested for antibacterial activity. 
2. Necessary controls were used. Like, 
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 Drug (Standard) control 
 Organism control 
 Gentamycin  (Known antibacterial agent) as reference was used in the 
present study. 
 Muller Hinton Agar (MHA) (Hi Media) was used as nutrient medium 
for growth of microorganisms. 
 The cultures used for testing were obtained from NCL which were 
equivalent to ATCC cultures. 
 All microorganisms were inoculated in Tryptic Soya Bean Broth (Hi 
Media). 
 All the drugs were dissolved in sterile Methanol and DMSO (AR 
Grade). 
3. The dissolved drugs were serially diluted according to NCCLS guidelines. 
4. Microbial strain: 
Name of Microorganism Used  Type    Strain Used  
A. Staphylococcus-aureus.  (Gram Positive)  ATCC 25923 
B. Bacillus-subtilis    (Gram Positive)   ATCC 21332 
C. Pseudomonas-aeruginosa. (Gram Negative)  ATCC 27853 
D. Escherichia-coli.   (Gram Negative)  ATCC 25922 
 
5. Sterile molten MHA was poured aseptically under laminar air flow unit into 
sterile Petri plates containing the test microorganism and was allowed to 
solidify. After solidification of the media cups/wells were bored using ‘T’ 
borer. 
6. The serially diluted antibacterial test solution(synthesized compounds) 
concentrations are 50µg/ml, 75µg/ml and 100 µg/ml were added in the cups 
and allowed to diffuse in the agar by placing the Petri plates under refrigeration 
for 10 minutes. 
7. At 370C all the plates stood incubated for 24 hours.  
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8. The inhibition zone of the test antibacterial solution and the control drug was 
measured using Vernier callipers and the MIC was determined.   
 
Preparation of different media: 
 The growth media required for evaluation of antibacterial activity was 
prepared as per the procedure reported in Himedia manual, as follows: 
 
1. Muller Hinton Agar: 
It mainly contains following content, 
 
Ingredients       Quantity (Gm/L) 
Beef heart infusion,       2.00 
Casein acid hydrolysate     17.50 
Starch, soluble      1.50 
Agar        17.00 
 
Procedure: 
 Suspend 38 grams in 1000ml distilled water. Mix well and boil the 
media to dissolve completely. autoclaving at 15 lbs pressure (1210C) for 15min 
sterilisation has done. Pour the media after mixing thoroughly. 
 
2. Tryptic soya bean broth:  
It mainly contains following content 
Ingredients       Quantity (Gm/L) 
Casein (enzymic hydrolysate)    18.00 
Papaic digest of soybean      2.00 
Sodium chloride      6.00 
Dipotassium phosphate     3.50 
Dextrose       3.50 
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Procedure: 
 Suspend 30grams of Tryptic soya bean broth powder in one litre of 
distilled water. Medium was boiled to dissolve completely. Autoclaving at 
15lbs pressure (1210C) for 15 minutes. 
 
Methods used for primary and secondary screening: 
Primary screening method, the test and control drugs were diluted 
using sterile methanol in 1000 microgram per ml (µg/ml), 500.0 microgram per 
ml , 250.0 microgram per ml from which 100 µl of solution taken in the cups to 
obtain a concentration of 100 microgram per ml, 75 microgram per ml and 50 
microgram per ml respectively. A methanol control was also run along with 
test and the reference drug. The promised result from the synthesized 
molecules was tested by primary screening for all microorganisms by second 
set dilution. 
Secondary screening method, The promised results from the 
synthesized molecules in primary screening were diluted using sterile methanol 
as 100 microgram per ml, 75 microgram per ml, 50 microgram per ml from 
which 100 µl of solution taken in the cups to obtain concentration of 0.8 
microgram per ml, 0.4 microgram per ml, 0.2 microgram per ml respectively. 
 
 
 
 
 
 
 
 
 
Fig No 20: Photographs showing zone of inhibition of IMP-DAL 1 
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Fig No 21: Photographs showing zone of inhibition of IMP-DAL 2 
 
 
 
 
 
 
 
 
 
Fig No 22: Photographs showing zone of inhibition of IMP-DAL 3 
 
 
 
 
 
 
 
 
 
Fig No 23: Photographs showing zone of inhibition of IMP-DAL 4 
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Fig No 24: Photographs showing zone of inhibition of IMP-DAL 5 
 
 
 
 
 
 
 
Fig No 25: Photographs showing zone of inhibition of IMP-DAL 6 
 
 
 
 
 
 
 
 
 
Fig No 26: Photographs showing zone of inhibition of IMP-DAL 7 
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7.1 RESULTS 
 
IMP-DAL 1 
 
N
NHN
NH
 
 
1. Molecular formula  :  C10H10N4 
2. Molecular wt   :  186.21 
3. Molecular composition :  C(64.50%), H(5.41%), N(30.09%). 
4. Melting point  :   240oC 
5. Colour   :  Brown 
6. State    :  Solid 
7. Rf value   :  0.16 
8. Percentage yield  :  60% 
9. NMR data   :    8.39-8.41 (doublet, 4H -Ar), 8.19 - 8.21  
       (doublet, 4H-Ar), 3.39 (Singlet, 1H, -NH),  
       3.29 (Singlet, 1H) 
     10. HPLC purity   :  92.15% 
     11. Mass data   :  m/z ratio 185.1 
     12. Solubility             :  Methanol , DMSO 
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Fig No 27:  LC-MS  Spectrum For Title Compound IMP-DAL 1 
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Fig No 28:  HPLC  Spectrum For Title Compound IMP-DAL 1 
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 Fig No 29: 1H NMR  Spectrum For Title Compound IMP-DAL 1 
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IMP-DAL 2 
 
N
NH2
O
 
 
1. Molecular formula  :  C5H6N2O 
2. Molecular wt   :  110.11 
3. Molecular composition :  C(54.54%), H(5.49%), N(25.44%), O  
       (14.53%). 
4. Melting point  :   180oC - 181oC 
5. Colour   :  Brown 
6. State    :  Solid 
7. Rf value   :  0.23 
8. Percentage yield  :  48.71% 
 9.   NMR data   :   7.75-7.77 (Singlet, 2 H, -Ar), 8.38-8.40  
      (doublet, 2H, -Ar), 6.48-6.50  
       (multiplet, 2H, NH) 
     10. HPLC purity   :  94.42% 
     11.  Mass data   :   m/z ratio 111.2 
     12. Solubility             :  Methanol , DMSO 
 
 
 
  
Results and Discussion  
Page 66 
 
 
 
 Fig No 30:  LC-MS Spectrum For Title Compound IMP-DAL 2 
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Fig No 31:  HPLC Spectrum For Title Compound IMP-DAL 2 
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Fig No 32:  1H NMR  Spectrum For Title Compound IMP-DAL 2 
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IMP-DAL 3 
N
NH2
 
 
1. Molecular formula  :  C6H5N2 
2. Molecular wt   :  94.11  
3. Molecular composition :  C(63.81%), H(6.43%), N(29.77%). 
4. Melting point  :  56°C-58°C 
5. Colour   :  Off - white 
6. State    :  Solid 
7. Rf value   :  0.54 
8. Percentage yield  :  80% 
9.  NMR data   :   7.86-7.87 (multiplet, 1 H, - Ar),  
       7.29-7.33 (multiplet, 1 H, -Ar), 6.39 – 6.44  
      (multiplet, 2 H, -Ar), 5.85(singlet, 2 H, -NH2). 
     10.  HPLC purity   :  99.93% 
     11.  Mass data   :   m/z ratio 96.4 
    12. Solubility             :  Methanol 
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 Fig No 33:  LCMS Spectrum For Title Compound IMP-DAL 3 
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Fig No 34:  HPLC Spectrum For Title Compound IMP-DAL 3 
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Fig No 35:  1H NMR Spectrum For Title Compound IMP-DAL 3 
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IMP-DAL 4 
N
NH2
 
 
1. Molecular formula  :  C6H5N2 
2. Molecular wt   :  94.11 
3. Molecular composition :  C(63.81%), H(6.43%), N(29.77%). 
4. Melting point  :  56°C-58°C 
5. Colour   :  Brown 
6. State    :  Solid 
7. Rf value   :  0.76 
8. Percentage yield  :  66.66% 
 9.   NMR data   :    7.80-8.00 (doublet, 1 H, -Ar), 6.80-7.00  
       (multiplet, 1 H, -Ar), 6.96-6.99  
       (multiplet, 1 H, -Ar), 6.86-6.89  
       (multiplet, 1 H, -Ar), 5.24 (singlet, 2 H, -NH2). 
     10.  HPLC purity   :  99.05% 
     11.  Mass data   :   m/z ratio 92.8 
     12. Solubility             :  Methanol  
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Fig No 36:  LC-MS Spectrum For Title Compound IMP-DAL 4 
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Fig No 37:  HPLC Spectrum For Title Compound IMP-DAL 4 
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Fig No 38:  1H NMR Spectrum For Title Compound IMP-DAL 4 
 
 
  
Results and Discussion  
Page 77 
IMP-DAL 5 
N
O NH2
 
 
1. Molecular formula  :   C6H6N2O 
2. Molecular wt   :   122.14 g/mol 
3. Molecular composition : C(59.01%), H(4.95%), N(22.94%),  
      O(13.10%). 
4. Melting point  :   155°C-157°C 
5. Colour   :   White 
6. State    :   Solid 
7. Rf value   :   0.73 
8. Percentage yield  :   95% 
9. NMR Data   :    8.68-8.70 (multiplet, 2H, -Ar),  
      8.22 (singlet, 1H, -Ar), 7.72-7.74 
       (multiplet, 2H, -Ar), 7.71 (singlet, 2H ,  
      -CO-NH2)                                                 
     10.   HPLC purity  :   99.05%   
     11.   Mass data   :   m/z ratio 122.2 
     12. Solubility             :  Methanol , DMSO 
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Fig No 39: LC-MS Spectrum For Title Compound IMP-DAL 5 
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 Fig No 40:  HPLC Spectrum For Title Compound IMP-DAL 5 
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 Fig No 41:  1H NMR Spectrum For Title Compound IMP-DAL 5 
 
  
Results and Discussion  
Page 81 
IMP-DAL 6  
N
O OH
 
 
1. Molecular formula  :   C6H5NO2 
2. Molecular wt   :   123.11  
3. Molecular composition : C(58.54%), H(4.09%), N(11.38%),  
      O(25.99%). 
4. Melting point  :   310oC  
5. Colour   :   White 
6. State    :   Solid 
7. Rf value   :   0.36 
8. Percentage yield  :   70.17% 
 9.    NMR data   :    13.9 (Singlet, 1 H, - COOH), 8.74-8.75 
       (doublet, 2 H, - Ar), 7.77-7.79 (doublet,  
        2 H, - Ar). 
     10.   HPLC purity  :   99.70% 
     11.   Mass data   :   m/z ratio 122.2 
     12. Solubility             :  Methanol , DMSO 
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Fig No 42:  LC-MS Spectrum For Title Compound IMP-DAL 6 
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 Fig No 43:   HPLC Spectrum For Title Compound IMP-DAL 6 
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Fig No 44:  1H NMR Spectrum For Title Compound IMP-DAL 6 
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IMP-DAL 7 
N
H
O
N
H
NN
 
 
1. Molecular formula  :   C11H10N4O 
2. Molecular wt   :   214.22 
3. Molecular composition : C(61.67%), H(4.71%), N(26.15%),  
       O(7.47%). 
4. Melting point  :   56°C-58°C 
5. Colour   :   Off-white 
6. State    :   Solid 
7. Rf value   :   0.54 
8. Percentage yield  :   22.22% 
9.    NMR data   :    9.41(Singlet, 2 H, -CONH), 8.38-8.40  
      (multiplet, 4 H, -Ar), 7.44-7.78 (multiplet,  
       4 H , - Ar). 
     10.   HPLC purity  :   96.62% 
     11.   Mass data   :   m/z ratio 215.2 
12. Solubility              :  Water 
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Fig No 45:  LC-MS Spectrum For Title Compound IMP-DAL 7 
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Fig No 46:  HPLC Spectrum For Title Compound IMP-DAL 7 
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 Fig No 47:  1H NMR Spectrum For Title Compound IMP-DAL 7 
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ANTIBACTERIAL ACTIVITY RESULTS OF IMP-DAL 1: 
Antibacterial Activity by Well Diffusion Method 
 
S. No. Concentration (µg/ml) 
Bacterial Culture 
Zone of Inhibition in mm 
E.coli P.aeruginosa S. aureus B.subtilis 
1 Std (Gentamicin) 26 25 25 26 
2 50 15 14 15 13 
3 75 17 18 17 17 
4 100 22 21 20 20 
 
Table No 10:  Zone of Inhibition of IMP-DAL 1. 
 
 
Fig No 48:  Zone of Inhibition of IMP-DAL 1. 
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ANTIBACTERIAL ACTIVITY RESULTS OF IMP-DAL 2 
S. No. Concentration (µg/ml) 
Bacterial Culture 
Zone of Inhibition in mm 
E.coli P.aeruginosa S. aureus B.subtilis 
1 Std (Gentamicin) 25 25 26 26 
2 50 10 08 08 09 
3 75 13 13 12 12 
4 100 15 15 13 14 
   Table No 11: Zone of Inhibition of IMP-DAL 2 
.
 
 
Fig No 49:  Zone of Inhibition of IMP-DAL 2. 
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ANTIBACTERIAL ACTIVITY RESULTS OF IMP-DAL 3: 
  
S. No. Concentration (µg/ml) 
Bacterial Culture 
Zone of Inhibition in mm 
E.coli P.aeruginosa 
S. 
aureus B.subtilis 
1 Std (Gentamicin) 25 26 26 26 
2 50 07 06 06 04 
3 75 10 10 08 09 
4 100 12 11 10 11 
 
Table No 12: Zone of Inhibition of IMP-DAL 3 
 
 
 
Fig No 50:  Zone of Inhibition of IMP-DAL 3. 
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ANTIBACTERIAL ACTIVITY RESULTS OF IMP-DAL 4: 
   
S. No. Concentration (µg/ml) 
Bacterial Culture 
Zone of Inhibition in mm 
E.coli P.aeruginosa S. aureus B.subtilis 
1 Std (Gentamicin) 25 25 25 26 
2 50 03 05 05 08 
3 75 08 07 05 07 
4 100 12 11 11 12 
 
Table No 13: Zone of Inhibition of IMP-DAL 4 
 
 
 
 
Fig No 51:  Zone of Inhibition of IMP-DAL 4. 
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ANTIBACTERIAL ACTIVITY RESULTS OF IMP-DAL 5: 
 
S. No. Concentration (µg/ml) 
Bacterial Culture 
Zone of Inhibition in mm 
E.coli P.aeruginosa S. aureus B.subtilis 
1 Std (Gentamicin) 26 26 25 25 
2 50 05 04 04 05 
3 75 07 06 06 06 
4 100 09 10 10 08 
 
Table No 14: Zone of Inhibition of IMP-DAL 5 
 
 
 
 
Fig No 52:  Zone of Inhibition of IMP-DAL 5. 
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ANTIBACTERIAL ACTIVITY RESULTS OF IMP-DAL 6: 
 
S. No. Concentration (µg/ml) 
Bacterial Culture 
Zone of Inhibition in mm 
E.coli P.aeruginosa S. aureus B.subtilis 
1 Std (Gentamicin) 25 25 26 26 
2 50 05 05 06 05 
3 75 08 07 06 06 
4 100 12 11 12 12 
 
Table No 15: Zone of Inhibition of IMP-DAL 6 
 
 
 
Fig No 53:  Zone of Inhibition of IMP-DAL 6. 
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ANTIBACTERIAL ACTIVITY RESULTS OF IMP-DAL 7: 
 
S. No. Concentration (µg/ml) 
Bacterial Culture 
Zone of Inhibition in mm 
E.coli P.aeruginosa S. aureus B.subtilis 
1 Std (Gentamicin) 25 25 26 25 
2 50 09 07 08 09 
3 75 11 12 11 12 
4 100 18 17 18 18 
 
Table No 16: Zone of Inhibition of IMP-DAL 7 
 
 
 
Fig No 54:  Zone of Inhibition of IMP-DAL 7. 
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PERCENTAGE ZONE OF INHIBITION OF SYNTHESIZED 
DALFAMPRIDINE GENOTOXIC IMPURITIES 
Compound 
code 
 
 
E.coli P.aeruginosa S. aureus B.subtilis 
Inhibition 
zone in 
mm 
% of 
inhibitio
n 
Inhibition 
zone in 
mm 
% of 
inhibitio
n 
Inhibition 
zone in 
mm 
% of 
inhibitio
n 
Inhibition 
zone in 
mm 
% of 
inhibition 
 
STANDAR
D 25 100.00 26 100.00 26 100.00 25 100.00 
IMP-DAL 1 22 88.00 21 80.76 20 76.92 20 80.00 
IMP-DAL 2 15 60.00 15 57.69 13 50.00 14 56.00 
IMP-DAL 3 12 48.00 11 42.30 10 38.46 11 44.00 
IMP-DAL 4 12 48.00 11 42.30 11 42.30 12 48.00 
IMP-DAL 5 09 36.00 10 38.46 10 38.46 08 32.00 
IMP-DAL 6 12 48.00 11 42.30 12 46.15 12 48.00 
IMP-DAL 7 18 72.00 17 65.38 18 69.23 18 72.00 
  
Table No 17 :  Percentage Zone of Inhibition for standard and synthesized 
compounds 
 
 
Fig No 55:  Percentage Zone of Inhibition for standard and synthesized 
compounds 
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7.2 DISCUSSION 
Dalfampridine is an organic compound with the chemical formula 
C5H4N-NH2 and molecular weight 94.04 gm/mole. It is chemically pyridine-4-
amine, used primarily as a research tool for subtypes of potassium channels. It 
is use to manage some of the symptoms of multiple sclerosis and is indicated 
for symptomatic improvement of walking in adults with several variations of 
the disease. It is very effective avicide and bird repellent and is highly toxic to 
human; it strongly excites central nervous system.  
Fampridine is also marketed as ampyra in the United States by Acorda 
Therapeutics and as Fampyra in Europe. In Canada, the medication has been 
approved for use by Health Canada since February 10, 2012. Dalfampridine is 
a non-selective K+ channel blocker, which can block a wide variety of K+ 
channels with different state dependences. Therefore, in search for clues for the 
structural determinants of K+ channels that are important for the state 
dependences of drug-channel interactions, 4-AP serves as a useful tool. 
Potassium channel blocker used to help multiple sclerosis patients walk. This is 
the first drug that was specifically approved to help with mobility in these 
patients. Fampridine has been shown to improve visual function and motor 
skills and relieve fatigue in patients with multiple sclerosis (MS). 
Dalfampridine impurities are synthesized, characterized and evaluated 
such as 1,2-Di(pyridine-4-yl)hydrazine, 4-Aminopyridine-N-oxide, 2-
Aminopyridine, 3-Aminopyridine, Pyridine-4-carboxamide, Pyridine-4-
carboxylic acid, (1, 3-Di (pyridin-4-yl) urea. Name of that synthesized 
recations and detailed descriptions, difficulties during synthesis and evaluation 
were discussed below: 
N-oxidation:  Pyridine N- oxidation was tried with mCPBA but the result was 
not achieved since oxidation of nitrogen is very poor. Alternatively hydrogen 
peroxide was used in presence of acetic acid gives us oxidized product.  
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Azo formation : Chemistry involved in formation of diazo group by using 
nitro compounds is very new and coupling reagents were tried with titanium 
chloride in presence stannous chloride. And reaction was achieved by using 
stannous chloride in presence of aqueous base. 
N- deoxygenation: Selective N- deoxidation in presence of diazo group was 
very challenging since possibility of aza bond breakage observed by using 
palladium carbon metallic reagent in presence of hydrogen. Alternatively 
selection of metallic reagents was done with repetitive trials with available 
literature source. 
To achieve selective deoxigenation 1 eqivalent of raney nickel was used in 
presence of hydrogen 5 mbar pressure so controlled removal of two unit of 
oxygens in pyridine was achieved successfully.  
Selective diazo Reduction : Collected literature says reduction was performed 
by metallic reagents in presence of hydrogen and the same chemistry was 
applied to get the desired product but achievement was not done. So extensive 
literature was made, hydrazine hydrate was the selective reagent for the diazo 
reduction of pyridine     containing nucleus and it was achieved to get targeted 
molecule successfully. 
Nitro to amine reduction of pyridine containing N- oxide:  Pyridine N oxide 
group was very sensitive towards palladium carbon / hydrogen exposure and 
very unstable. By understanding  the chemistry of pyridine N- oxide nucleus, 
nitro reduction was achieved with controlled hydrogen pressure with minimal 
usage of metallic reagent like palladium carbon.  
Nitro to amine reduction : Zinc ammonium formate was used in presence of 
methanol as a suitable solvent to form zinc amalgam complex,  formed 
complex helped to reduce nitro group of pyridine nucleus with higher rate of 
reaction helps us to get the good yield of targeted molecule. 
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Diamide formation : Pyridine amines was successfully coverted to amide 
linkage by the usage of 1,1’ Carbonyl Di imidazole. Carbonyl group from the 
CDI drawn the amine proton to form diamides pyridine nucleus.   
Antibacterial activity: 
The synthesized dalfampridine genotoxic impurities were evaluated against 
gram +ve bacteria like Staphylococcus-aureus, Bacillus-subtilis and gram -ve 
bacteria like Pseudomonas-aeruginosa, Escherichia-coli  using standard drug 
Gentamycin. Zone of inhibition in mm was determined. The results were listed 
in table No. . The explanations revealed that, IMP-DAL 1, IMP-DAL 2, IMP-
DAL 7 exhibits substantial antibacterial activity against and its direction 
Escherichia-coli ˃ Pseudomonas-aeruginosa ˃ Bacillus-subtilis ˃ 
Staphylococcus-aureus.  IMP-DAL 3, IMP-DAL 4, IMP-DAL 5, IMP-DAL 6 
also have antibacterial activity but its showed mild antibacterial activity 
contrary to gram +ve bacteria and gram -ve bacteria test organisms. 
Concentration of test solutions were 100 µg/ml, 75 µg/ml and 50 µg/ml used 
for antibacterial study but 100 µg/ml is showed more activity compared to 
other concentrations. 
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8.1 SUMMARY  
 
 Main aim and focus of research work has been designed to prepared 
dalfampridine genotoxic impurities with different types of reaction 
mechanisams like, selective nitration, nitro to amine conversion, N- oxidation, 
diazotitation, azo coupling, reduction of N=N by hydrazine hydrate, N- 
deoxygenation, acid to acid chloride formation, mono and di amide formation.  
 
Section 1, gives an introduction to the development, biological importance 
endowed by compounds containing dalfampridine impurities which has 
different substitutions. The chemistry of Dalfampridine and synthetic methods 
of Dalfampridine has also been illustrated briefly. 
 
Section 2, focuses on the aim and scope of the work, entire research of this 
dissertation by explaining the need to develop newer compounds and to make 
the synthetic routes more appropriate by different reaction applications. 
 
Section 3, an elaborated review of literature of various substituted 
Dalfampridine and its impurities with which their biological activity and 
genotoxicity of fampridine impurity  has been described. 
 
Section 4, deals with the details regarding the chemicals, reagents, culture 
media, test organisams and methodology used in the entire research work. This 
section also provides the synthetic schemes used to synthesize the intermediate, 
final compounds and preliminary screening of antibacterial activity of 
synthesized compounds . The physical constants, TLC, recrystallisation 
solvents of the synthesized compounds were also incorporated in this section.  
 
Section 5, all the synthesised molecules were characterized by subjecting to 
analytical studies like 1H-NMR, LCMS and HPLC spectroscopy. All the final 
molecules assessed for in-vitro antibacterial action on gram + ve and gram - ve 
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bacteria using standard drug Gentamycin. This section  deals with the details of 
pharmacological activity results of anti-bacterial property of the synthesized 
compounds.  
 
Section 6, deals with the details of synthesise of individual molecule, problem 
faced during the synthesis, the spectral analyses with reasoning and discusses 
on the results of antibacterial activity. 
 
Section 7, deals with summarise the every step of Dalfampridine impurities 
synthesis, identification, characterization and its biological activity of this 
dissertation work. summarizes all the theoretical and experimental activities 
and topics that led to the formation of this dissertation. 
 
Section 8, a conclusion of the work in relation to objectives and the results 
obtained has been depicted. 
 
Section 9, enlists all the references that led to the formation of this dissertation. 
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8.2 CONCLUSION 
 From the planned reaction mechanism and chemistry of pyridine nucleus 
was understood made an attempt to synthesize different pyridine derivatives, 
that is fampridine genotoxic impurities from waste application of chemical 
reactions like N-oxidation, Azo formation, N- deoxygenation, selective 
deoxigenation, Selective diazo Reduction, Nitro to amine reduction of pyridine 
containing N- oxide, Nitro to amine reduction, Diamide formation. 
  All the targeted molecules synthesized with good yield and high purity. 
To achieve high purity attention was drawn forwards automated combiflash 
and it was performed by developing different analytical methods for separation 
of synthesized genotoxic impurities.  
 The synthesized genotoxic impurities were characterized using 
hyponated analytical instruments like NMR, LCMS-MS, HPLC Combiflash. 
 
 The HPLC purity of genotoxic impurities listed below 
S.NO NAME OF THE IMPURITY % PURITY 
1. IMP-DAL 3 99.93% 
2. IMP-DAL 6 99.70% 
3. IMP-DAL 4 99.05% 
4. IMP-DAL 5 99.05% 
5. IMP-DAL 7 96.62% 
6. IMP-DAL 2 94.42% 
7. IMP-DAL 1 92.15% 
 
Table No 18:  HPLC purity of synthesized dalfampridine genotoxic impurities 
 
 By the above achievement and all the characterization data’s of 
genotoxic impurities can be used as reference standards in pharmaceutical 
industry to evaluate the drug substance.  
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 Novel produced compounds, assessed for its in-vitro anti-bacterial 
activity compared to both gram-positive and gram-negative bacteria using the 
standard drug Gentamycin. It was concluded as IMP-DAL 1, IMP-DAL 2, 
IMP-DAL 7 exhibited substantial antibacterial activity against its direction 
Escherichia-coli ˃ Pseudomonas-aeruginosa ˃ Bacillus-subtilis ˃ 
Staphylococcus-aureus. IMP-DAL 3, IMP-DAL 4, IMP-DAL 5, IMP-DAL 6 
showed mild antibacterial activity contrary to gram +ve bacteria and gram -ve 
bacteria test organisms. 100 µg/ml of synthesized molecules showed more 
activity compared to other concentrations. 
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N NH 
Certificate of Analysis 
DALFAMPRIDINE DIMER 
IMPURITY 
(REFERENCE SUBSTANCE) 
 
 
 
 
 
 
1,2-Bis(4-pyridyl)hydrazine 
PURITY (HPLC): 92.1% 
 
CATALOG #: 100287  Lot #: PADM/IMP/295 
PACK SIZE: 85 mg  CAS #: 19808-51-6 
DATE OF COA: 03 January 2018    
EXPIRATION DATE: 02 January 2019 
RECEIPT DATE:   
 
Note: This space is provided for convenience only and its use is not required. 
STORAGE: Store at 2˚C to 8˚C. 
CHEMICAL FORMULA: C₁₀H₁₀N₄ Molecular weight: 186.21 g/mol 
PHYSICAL DESCRIPTION:Brown solid.    
HAZARDS: Read Safety data sheet before using. All chemical reference materials should be 
considered potentially hazardous and should be used only by qualified laboratory personnel. 
INSTRUCTIONS FOR USE: Do not dry, use as is. The internal pressure of container may be 
slightly different from the atmospheric pressure at the user’s location. Open slowly and carefully to
avoid dispersion of the material. This material is intended for Analytical use only. Not for drug, 
human consumption household or other uses. 
 
HN N 
Certificate of Analysis 
DALFAMPRIDINE N-
OXIDE IMPURITY 
(REFERENCE SUBSTANCE) 
 
4-Pyridinamine 1-Oxide 
PURITY (HPLC): 94.4% 
 
CATALOG #: 100289  Lot #: PADM/IMP/297 
PACK SIZE: 125 mg  CAS #: 3535-75-9 
DATE OF 
COA: 
27 December 2017    
EXPIRATION DATE: 26 December 2018 
RECEIPT DATE:   
Note: This space is provided for convenience only and its use is not required. 
STORAGE: Store at 2˚C to 8˚C. 
CHEMICAL FORMULA: C4H₆N₂O Molecular weight: 110.11 g/mol 
PHYSICAL 
DESCRIPTION: 
Brown solid.    
HAZARDS: Read Safety data sheet before using. All chemical reference materials should be 
considered potentially hazardous and should be used only by qualified laboratory personnel. 
INSTRUCTIONS FOR USE: Do not dry, use as is. The internal pressure of container may be 
slightly different from the atmospheric pressure at the user’s location. Open slowly and carefully to 
avoid dispersion of the material. This material is intended for Analytical use only. Not for drug, 
human consumption household or other uses. 
 
Certificate of Analysis 
ISONICOTINAMIDE 
(REFERENCE SUBSTANCE) 
4-Pyridinecarboxamide 
 
[ 
PURITY (HPLC): 99.1% 
 
CATALOG #: 100320  Lot #: PADM/IMP/328 
PACK SIZE: 100 mg  CAS #: 1453-82-3 
DATE OF COA: 10 November 2017    
EXPIRATION DATE: 09 November 2018 
RECEIPT DATE:   
Note: This space is provided for convenience only and its use is not required. 
STORAGE: Store at 2˚C to 8˚C. 
CHEMICAL FORMULA: C5H₆N₂O Molecular 
weight: 
122.12 g/mol 
PHYSICAL DESCRIPTION: White solid.    
HAZARDS: Read Safety data sheet before using. All chemical reference materials should be 
considered potentially hazardous and should be used only by qualified laboratory personnel. 
INSTRUCTIONS FOR USE: Do not dry, use as is. The internal pressure of container may be 
slightly different from the atmospheric pressure at the user’s location. Open slowly and carefully to 
avoid dispersion of the material. This material is intended for Analytical use only. Not for drug, 
human consumption household or other uses. 
 
  
Certificate of Analysis 
3-AMINOPYRIDINE 
(REFERENCE SUBSTANCE) 
3-Pyridinamine 
 
[ 
PURITY (HPLC): 99.1% 
 
CATALOG #: 100321  Lot #: PADM/IMP/329 
PACK SIZE: 45 mg  CAS #: 462-08-8  
DATE OF 
COA: 
10 November 2017    
EXPIRATION DATE: 09 November 2018 
RECEIPT DATE:   
 
Note: This space is provided for convenience only and its use is not required. 
STORAGE: Store at 2˚C to 8˚C. 
CHEMICAL FORMULA: C5H₆N₂ Molecular 
weight: 
94.11 g/mol 
PHYSICAL 
DESCRIPTION: 
Brown solid.    
HAZARDS: Read Safety data sheet before using. All chemical reference materials should be 
considered potentially hazardous and should be used only by qualified laboratory personnel. 
INSTRUCTIONS FOR USE: Do not dry, use as is. The internal pressure of container may be 
slightly different from the atmospheric pressure at the user’s location. Open slowly and carefully 
to avoid dispersion of the material. This material is intended for Analytical use only. Not for 
drug, human consumption household or other uses. 
 
  
Certificate of Analysis 
2-AMINOPYRIDINE 
(REFERENCE SUBSTANCE) 
 
2-Pyridinamine 
[ 
PURITY (HPLC): 99.9% 
 
CATALOG #: 100322  Lot #: PADM/IMP/330 
PACK SIZE: 190 mg  CAS #: 504-29-0  
DATE OF COA: 10 November 2017    
EXPIRATION DATE: 09 November 2018 
RECEIPT DATE:   
 
Note: This space is provided for convenience only and its use is not required. 
STORAGE: Store at 2˚C to 8˚C. 
CHEMICAL FORMULA: C₅H₆N₂ Molecular weight: 94.11 g/mol 
PHYSICAL DESCRIPTION: White solid.    
HAZARDS: Read Safety data sheet before using. All chemical reference materials should be 
considered potentially hazardous and should be used only by qualified laboratory personnel. 
INSTRUCTIONS FOR USE: Do not dry, use as is. The internal pressure of container may be 
slightly different from the atmospheric pressure at the user’s location. Open slowly and carefully to 
avoid dispersion of the material. This material is intended for Analytical use only. Not for drug, 
human consumption household or other uses. 
 
  
Certificate of Analysis 
ISONICOTINIC ACID 
(REFERENCE SUBSTANCE) 
 
4-Pyridinecarboxylic Acid 
 
[ 
PURITY (HPLC): 99.7% 
 
CATALOG #: 100323  Lot #: PADM/IMP/331 
PACK SIZE: 170 mg  CAS #: 55-22-1  
DATE OF COA: 10 November 2017    
EXPIRATION DATE: 09 November 2018 
RECEIPT DATE:   
 
Note: This space is provided for convenience only and its use is not required. 
STORAGE: Store at 2˚C to 8˚C. 
CHEMICAL FORMULA: C₆H₅NO₂ Molecular weight: 123.11 g/mol 
PHYSICAL DESCRIPTION: White solid.    
HAZARDS: Read Safety data sheet before using. All chemical reference materials should be 
considered potentially hazardous and should be used only by qualified laboratory personnel. 
INSTRUCTIONS FOR USE: Do not dry, use as is. The internal pressure of container may be 
slightly different from the atmospheric pressure at the user’s location. Open slowly and carefully to 
avoid dispersion of the material. This material is intended for Analytical use only. Not for drug, 
human consumption household or other uses. 
 
 
